Original Article
Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy
N Engl J Med 1999; 341:468-475August 12, 1999
- Abstract
Background
Pollen immunotherapy is effective in selected patients with IgE-mediated seasonal allergic rhinitis, although it is questionable whether there is long-term benefit after the discontinuation of treatment.
Methods
We conducted a randomized, double-blind, placebo-controlled trial of the discontinuation of immunotherapy for grass-pollen allergy in patients in whom three to four years of this treatment had previously been shown to be effective. During the three years of this trial, primary outcome measures were scores for seasonal symptoms and the use of rescue medication. Objective measures included the immediate conjunctival response and the immediate and late skin responses to allergen challenge. Cutaneous-biopsy specimens obtained 24 hours after intradermal allergen challenge were examined for T-cell infiltration and the presence of cytokine-producing T helper cells (TH2 cells) (as evidenced by the presence of interleukin-4 messenger RNA). A matched group of patients with hay fever who had not received immunotherapy was followed as a control for the natural course of the disease.
Results
Scores for seasonal symptoms and the use of rescue antiallergic medication, which included short courses of prednisolone, remained low after the discontinuation of immunotherapy, and there was no significant difference between patients who continued immunotherapy and those who discontinued it. Symptom scores in both treatment groups (median areas under the curve in 1995, 921 for continuation of immunotherapy and 504 for discontinuation of immunotherapy; P=0.60) were markedly lower than those in the group that had not received immunotherapy (median value in 1995, 2863). Although there was a tendency for immediate sensitivity to allergen to return late after discontinuation, there was a sustained reduction in the late skin response and associated CD3+ T-cell infiltration and interleukin-4 messenger RNA expression.
Conclusions
Immunotherapy for grass-pollen allergy for three to four years induces prolonged clinical remission accompanied by a persistent alteration in immunologic reactivity.
Media in This Article
Figure 1
Median Weekly Pollen Counts and Symptom, Rescue-Medication, and Visual-Analogue Scores for the Initial Placebo Trial (1989) and for the Current Trial (1993 through 1995).Figure 2
Late Skin Responses and Number of CD3+ T Cells and Cells Containing Interleukin-4 mRNA in Skin-Biopsy Specimens Obtained 24 Hours after Intradermal Injection of Allergen or Diluent.Article Activity
- Article
Despite advances in pharmacotherapy for grass-pollen allergy, there has been a marked increase in the prevalence of summer hay fever in countries with a Western lifestyle.1 Although topical nasal corticosteroids and the new nonsedating antihistamines are highly effective in treating hay fever,2 there remains a group of patients who have a poor response to these treatments and for whom immunotherapy is currently recommended.3 An important question is whether allergen immunotherapy exerts a prolonged effect after it is discontinued. Such an effect would make this form of therapy attractive for prophylaxis and for early intervention.
We previously demonstrated the usefulness of immunotherapy in a cohort of patients with severe summer hay fever that could not be controlled by antiallergic drugs.4 We initially followed these patients for a four-year period. During the first year (1989), patients were randomly assigned to receive injections of either grass-pollen vaccine or placebo. The vaccine was highly effective in reducing symptoms and the need for rescue drugs. Efficacy was accompanied by decreased sensitivity of the conjunctiva and skin to allergen and by inhibition of the late skin response.4 Clinical improvement was maintained with continued immunotherapy during the ensuing three years.5
In the current, placebo-controlled study, we examined the effects of the discontinuation of immunotherapy for three years in the same group of patients. We also followed a matched group of patients who never received immunotherapy as a control for the natural history of the disease during this phase. Objective measures of outcome included immediate sensitivity of the conjunctiva and early and late skin responses to grass-pollen extract. Immunologic responsiveness was determined by assessing the late infiltration of CD3+ T lymphocytes and production of interleukin-4 in skin specimens 24 hours after intradermal grass-pollen challenge. We tested the hypothesis that in selected patients with IgE-mediated grass-pollen allergy, immunotherapy has a long-term effect and can modify the course of the disease.
Methods
Patients
In 1988, 40 patients were recruited from the Royal Brompton Hospital Allergy Clinic or through an advertisement in a local newspaper; these patients had a history of severe seasonal allergic rhinitis, poor control of symptoms in previous years despite regular use of antiallergic drugs, and a positive skin-prick test (wheal, >5 mm) to timothy grass-pollen extract. Patients were excluded if they had a clinical history of other allergies or important medical illnesses or if they had chronic asthma. Patients with mild seasonal asthma were included, provided their symptoms were controlled by inhaled sympathomimetic β2-adrenergic–agonist bronchodilators. Thirty-seven patients completed the initial one-year, double-blind, placebo-controlled study (1989).4 For patients who received placebo injections during that year, immunotherapy with grass-pollen extract was then initiated over a six-to-eight-week period, and subsequently 32 of the 37 patients completed maintenance therapy with grass-pollen injections for the following three years (1990 through 1992).5 In 1992, 15 matched patients with hay fever who had never received immunotherapy were recruited as a control group; the inclusion and exclusion criteria were identical to those used for the patients who received immunotherapy.
Study Design
The study was performed with the approval of the Royal Brompton Hospital ethics committee, and all the patients gave written informed consent. In 1992, 32 patients remained in the group receiving immunotherapy; analyses of data on these patients were stratified according to whether they had received three or four years of active immunotherapy before the current, double-blind randomization to either continued maintenance immunotherapy with depot grass-pollen vaccine (the maintenance group) or matched placebo injections (the discontinuation group). Injections of vaccine or placebo were given monthly for three years. The 15 matched patients who had never received immunotherapy (the control group) received no injections and were monitored in parallel. Patients in all three groups had equal access to the same rescue medication and underwent the same follow-up assessments.
Immunotherapy
A standardized, aluminum hydroxide–adsorbed, depot grass-pollen vaccine (Alutard SQ, ALK Abelló, Horsholm, Denmark) was used for subcutaneous-injection immunotherapy. Each monthly 1-ml maintenance injection contained 100,000 SQ units (equivalent to 10,000 biologic units6 and containing 20 μg of the phleum [timothy] allergen P5).6 Placebo injections consisted of identical vials of diluent, including aluminum hydroxide and 0.01 mg of histamine per milliliter. For three years, 1-ml injections were given monthly in the upper arm, except during the pollen seasons, when the maintenance dose was reduced by 40 percent. Patients were observed for one hour after each injection.
Assessments
Primary outcome measures were the presence of symptoms and the need for rescue medication. Patients recorded symptom scores and drug requirements every day from May through September of each year. Individual symptoms in the nose (sneezing, blockage, and running), eyes (itching, redness, tears, and swelling), mouth and throat (itching and dryness), and chest (breathlessness, cough, wheezing, and tightness) were recorded on a scale of 0 to 3 (with a score of 0 indicating no symptoms and 1, 2, and 3 indicating mild, moderate, and severe symptoms, respectively). Patients were given cromolyn sodium eye drops (Opticrom, Rhone-Poulenc, West Malling, United Kingdom), aqueous nasal spray (cromolyn sodium, Rynacrom, Laboratoires Fisons, Le Trait, France), a short-acting, nonsedating antihistamine, acrivastine (8-mg capsules, Semprex, Glaxo Wellcome, Greenford, United Kingdom), and an albuterol inhaler (Ventolin, Allen and Hanbury's, Stockley Park, United Kingdom) as rescue medications. If symptoms were not controlled, patients were advised to take, in addition, a seven-day course of prednisolone tablets (5-mg tablets; dosage, 30 mg per day for two days, with the dose successively reduced by 5 mg on each of the following five days).
Patients' diaries were scored by totaling individual symptom scores for each week, with a maximal possible score of 21 for each symptom. Drugs were scored as follows: each eye drop, dose of nasal spray, or inhalation of albuterol was given a score of 1, and each acrivastine capsule or prednisolone tablet was given a score of 2. Patients were asked every two weeks to record a visual-analogue score (on a scale of 0 to 10, where 0 indicated minimal symptoms and 10 indicated maximal symptoms) in response to the question, “How has your hay fever been during the past week?”
Objective measures of outcome were the immediate and late skin responses and the immediate conjunctival response to allergen challenge. They were assessed at the end of the study in November 1995. Skin-prick tests were performed in duplicate, with allergen concentrations of 100 to 100,000 SQ units per milliliter applied to the flexor aspect of the forearm. Immediate responses were recorded after 15 minutes and were expressed as the allergen concentration that caused a 6-mm wheal. Intradermal testing was performed on the extensor surface of the forearm with an injection of 10 SQ units of allergen in 0.02 ml of diluent and a control injection of diluent alone. Late responses were recorded as the mean diameter of the swelling at 24 hours.
Tests of the conjunctival response were performed by instilling half-log (approximately threefold) incremental concentrations of grass-pollen extract (100 to 100,000 SQ units per milliliter) into alternate eyes at 10-minute intervals. Immediate conjunctival sensitivity was recorded as the dose that induced a minimum of two of four symptoms (itching, redness, tears, or swelling). In both the skin and conjunctival tests, if there was no response at the highest concentration of allergen tested (100,000 SQ units per milliliter), the outcome was arbitrarily assigned a value of 300,000 SQ units per milliliter.
Skin Biopsies
Punch-biopsy specimens 3 mm in diameter were taken 24 hours after intradermal injection from both the site of allergen injection and the site of diluent (control) injection. CD3+ T cells and cells containing interleukin-4 messenger RNA (mRNA) were identified by immunohistochemical analysis and in situ hybridization of 6-μm cryostat sections of the biopsy specimens with appropriate negative controls, as previously described.7 All analyses were performed in a blinded manner.
Statistical Analysis
Symptom and medication scores were expressed as the area under the curve for the 11-week period that corresponded to the peak pollen season. The primary outcome was analyzed by comparing symptom and rescue-medication scores over the three-year period of the study for the maintenance group with scores for the discontinuation group. Visual-analogue scores during the pollen season, the results of skin and conjunctival tests, and cell counts in skin-biopsy sections were analyzed in the same way with use of the two-tailed Mann–Whitney U test8,9 (Minitab statistical software, State College, Pa.). P values of less than 0.05 were considered to indicate statistical significance.
Results
The three groups of patients were matched for sex and age. They were also matched for wheal size in response to skin-prick testing at enrollment (1988 for both immunotherapy groups and 1992 for the control group) (Table 1Table 1
Clinical Characteristics of the 47 Patients Studied from 1992 through 1995.). Throughout the current trial, weekly pollen counts in London peaked consistently in the average or above-average range (60 [±24] SE grains per cubic meter for the years 1989 to 1998) in June and July (Figure 1Figure 1Median Weekly Pollen Counts and Symptom, Rescue-Medication, and Visual-Analogue Scores for the Initial Placebo Trial (1989) and for the Current Trial (1993 through 1995).). Scores for total hay fever symptoms, rescue medication, and the visual-analogue scale for both the maintenance group and the discontinuation group were temporally related to pollen counts, remained low, and were similar to those recorded during the preceding three years, when all the patients in these two groups had received active immunotherapy.5 There were no significant differences in any of these scores between these two groups throughout the three-year period. Individual nose, eye, chest, mouth, and throat symptoms also remained similar between these two groups (Table 2Table 2
Scores for Symptoms, Rescue-Medication Use, and the Visual-Analogue Scale during the 1993, 1994, and 1995 Pollen Seasons.). In contrast, symptom and rescue-medication scores in both groups were markedly lower than those in patients in the control group (Figure 1 and Table 2). The need for one or more courses of prednisolone tablets during the three-year period was also markedly lower in the maintenance and discontinuation groups (3 of 16 patients in each group) than in the control group (9 of 15 patients).There was a tendency for immediate sensitivity to grass pollen to return three years after the discontinuation of immunotherapy. The concentration of grass-pollen extract required to cause a 6-mm wheal on skin-prick testing was significantly lower in the group that discontinued immunotherapy (median, 40,000 SQ units per milliliter; range, 3000 to 300,000) than in the group that received maintenance immunotherapy (median, 300,000 SQ units per milliliter; range, 60,000 to 300,000; P=0.005). There was also a trend in the discontinuation group toward a decrease in the grass-pollen concentration that elicited an immediate conjunctival response (median, 30,000 SQ units per milliliter; range, 300 to 300,000, as compared with 100,000 SQ units per milliliter; range, 3000 to 300,000, in the maintenance group; P=0.06). In the control group, however, the concentrations of allergen that caused an immediate wheal (median, 3000 SQ units per milliliter; range, 1000 to 10,000) and immediate conjunctival symptoms (median, 3000 SQ units per milliliter; range, 300 to 30,000) remained markedly lower than those in both immunotherapy groups (maintenance and withdrawal).
The control group had large (>3 cm) late skin responses 6 to 48 hours after the intradermal injection of grass pollen (Figure 2Figure 2
Late Skin Responses and Number of CD3+ T Cells and Cells Containing Interleukin-4 mRNA in Skin-Biopsy Specimens Obtained 24 Hours after Intradermal Injection of Allergen or Diluent.). Immunohistochemical analyses of biopsy specimens from the site of allergen injection, as compared with control sites, revealed marked infiltration at 24 hours by CD3+ T lymphocytes and an increase in cells containing interleukin-4 mRNA. In contrast, in both the maintenance group and the discontinuation group, the late skin response was virtually absent and there were fewer infiltrating CD3+ T cells and markedly fewer infiltrating cells containing interleukin-4 mRNA than in the control group (Figure 2). No differences were observed between these two groups in the late skin response as assessed on the basis of the size of the swelling (P=0.16) or in the numbers of CD3+ T cells (P=0.57) or cells containing interleukin-4 mRNA (P=0.87). In both immunotherapy groups, there was no correlation between the late skin responses and the corresponding immediate skin responses after intradermal injection of grass pollen (data not shown).Immunotherapy was well tolerated by the patients who received it throughout the three-year period. Less than 2 percent of injections resulted in early or delayed local reactions larger than 3 cm in diameter. No substantial immediate or late systemic reactions were observed after allergen injections. Thirty-nine of the 47 patients completed the study. During the second and third years of the study, 2 of the 16 patients in the maintenance group, 3 of the 16 in the discontinuation group, and 3 of the 15 in the control group dropped out. These patients withdrew for reasons unrelated to the study protocol. Blinding of the trial was checked at the end of the study by asking the patients and the investigator to guess which treatments (active [maintenance] or placebo [discontinuation]) the patients in the two immunotherapy groups had received. Sixteen of the 27 patients remaining in these two groups guessed correctly, whereas the investigator was correct in 15 of the 27 cases. These results were not significantly different from those that would have occurred by chance (P=0.5 for the patients' guesses, and P=0.8 for the investigator's guesses, by the chi-square test).
Discussion
We have shown, under double-blind conditions, that three to four years of grass-pollen immunotherapy remains effective for at least three years after the discontinuation of the injections. In both the group that received maintenance immunotherapy and the group that discontinued immunotherapy, clinical improvement was accompanied by a marked decrease in the late skin response to allergen challenge, blunting of the accompanying CD3+ T-cell infiltrate, and fewer interleukin-4 mRNA–expressing cells than in the control group. The results demonstrate prolonged clinical benefit and provide evidence of decreased immunologic reactivity for at least three years after the discontinuation of immunotherapy for the treatment of hay fever.
In contrast to the late skin response, there was a tendency for immediate sensitivity to grass pollen to return three years after discontinuation of immunotherapy, as reflected by the appearance of a small but significant difference in the immediate response to skin-prick testing and a trend toward an increase in conjunctival sensitivity (measured 15 minutes after allergen challenge) in the discontinuation group as compared with the maintenance group. However, this tendency was not accompanied by a return of symptoms, perhaps indicating that late responses have greater relevance than early responses to the clinical expression of hay fever.
The efficacy of grass-pollen immunotherapy in patients with seasonal hay fever has been confirmed in many controlled trials.3-5,7,10-16 Immunotherapy is also effective, although less so, in patients with seasonal asthma.14,17,18 In contrast, patients with perennial disease associated with sensitivity to multiple allergens are less responsive to this form of treatment.19
Previous studies have suggested that immunotherapy has a long-term effect.20-25 In a retrospective study of children who were sensitive to house-dust mites, short-term (12-month) immunotherapy was associated with a greater rate of relapse than was treatment for more than 3 years. In the only blinded study of the discontinuation of pollen immunotherapy, patients with sensitivity to ragweed were followed for one year; in a finding consistent with our own, a recurrence of immediate sensitivity to allergen was observed.26
T-cell–derived cytokines play a key part in allergic inflammation. Grass-pollen–specific T cells from patients with atopy produce greater quantities of cytokines such as interleukin-4, interleukin-13, and interleukin-5 (and thus can be identified as type 2 T helper cells [TH2])27,28 than do cells from control subjects without atopy, which favor the production of interferon-γ (TH1 cells).27,29 Interleukin-430 and interleukin-1331 stimulate IgE production by B cells and therefore promote the sensitization of high-affinity IgE receptors on the surface of mast cells and basophils, whereas interleukin-5 has specific pro-eosinophilic properties.32 IgE-dependent activation of mast cells results in an immediate response to allergen and may contribute to the development of the late response.33
Previous studies found decreases in serum IgE concentrations,34 increases in IgG,35 and inhibition of recruitment or activation of effector cells such as mast cells36,37 and eosinophils38,39 in the target organ in response to immunotherapy. Since each of these processes is thought to be largely T-cell–dependent, one possibility is that immunotherapy exerts a prolonged effect by altering the T-cell response to subsequent allergen exposure. Our earlier studies, performed in the same group of patients after they had received one year of immunotherapy, demonstrated inhibition of the late response in both nose and skin, accompanied by an increase in TH1 responses as detected by an increase in interferon-γ mRNA expression.7,40
Further studies of cutaneous-biopsy specimens obtained at 24 hours suggested that this TH1 response may have been driven by interleukin-12, since inhibition of the late skin response was accompanied by a marked increase in cells expressing interleukin-12 mRNA, predominantly tissue macrophages.41 Studies of T-cell responses in the peripheral blood of patients undergoing immunotherapy with pollen extract have revealed a corresponding reduction in TH2 responses, as shown by a decrease in interleukin-4.42,43 Taken together, these studies suggest that pollen immunotherapy may act either by inducing immune deviation of TH2 and TH0 T-cell responses in favor of TH1 responses or by diminishing TH2 and TH0 T-cell responses.44
In contrast to our earlier findings, the current finding of a decrease in the number of cells expressing interleukin-4 mRNA suggests that persistent suppression of TH2 responses may be responsible for sustained clinical improvement, as reflected by an inhibition of the late response, whereas immediate mast-cell–dependent responses to allergen may return several years after discontinuation of treatment. Since we did not identify the cellular source of interleukin-4 mRNA, it is possible that cells other than T cells, including basophils,45 mast cells,46 or eosinophils,47 contribute to the expression of this cytokine. Irrespective of the precise mechanism, these data provide objective evidence of a long-term immunologic effect after the discontinuation of immunotherapy.
The usefulness of allergen immunotherapy is highlighted in a recent World Health Organization report,3 which advocates its use in selected patients with specific IgE antibodies to clinically relevant allergens. Selection of patients is extremely important; the risk–benefit ratio is less favorable for patients with asthma than for those with allergic rhinitis. The rationale for prescribing allergen immunotherapy depends on the degree to which symptoms can be alleviated by medication and whether effective avoidance of allergen is possible. The quality of allergen vaccines is also critical, and an optimal maintenance dose of 5 to 20 μg of major allergen per injection (as in the current study) correlates with clinical efficacy.3
An important question has been whether immunotherapy has the potential to modify the long-term course of allergic disease after discontinuation.19-25 The current findings suggest that it does and raise the question of whether allergen-injection immunotherapy should be considered earlier in the course of allergic disease to prevent progression or, as suggested by another study,48 the development of multiple allergies. Further studies with long-term follow-up, particularly in children with limited allergic sensitivities, could address this possibility.
Supported by grants from the Medical Research Council and National Asthma Campaign, United Kingdom, and by funding from ALK Abelló, Horsholm, Denmark (to Ms. Walker).
We are indebted to ALK Abelló for providing allergen extracts for diagnosis and immunotherapy; to Jessica Harris, medical statistician at the Imperial College School of Medicine, for her advice; and to Dr. Jean Emberlin at the National Pollen Research Unit, University College, Worcester, United Kingdom, for providing the pollen counts.
Source Information
From the Department of Upper Respiratory Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, London (S.R.D., S.M.W., E.-M.V., M.R.J., F.O., W.N., S.J.T., K.T.N.-A.); the Allergy Clinic, Royal Brompton and Harefield National Health Service Trust, London (S.R.D., S.M.W.); and Meakins Christie Laboratories, McGill University, Montreal (Q.A.H.).
Address reprint requests to Dr. Durham at the Department of Upper Respiratory Medicine, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse St., London SW3 6LY, United Kingdom, or at s.durham@rbh.nthames.nhs.uk.
- References
References
1
von Mutius E ,Fritzsch C ,Weiland SK ,Roll G ,Magnussen H . Prevalence of asthma and allergic disorders among children in united Germany: a descriptive comparison. BMJ 1992;305:1395-1399
CrossRef | Web of Science | Medline2
The International Rhinitis Management Working Group
CrossRef | Web of Science | Medline3
Allergen immunotherapy: therapeutic vaccines for allergic diseases: Geneva: January 27-29, 1997Allergy 1998;44:Suppl:1-42
CrossRef | Web of Science4
Varney VA ,Gaga M ,Frew AJ ,Aber VR ,Kay AB ,Durham SR . Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265-269
CrossRef | Web of Science | Medline5
Walker SM ,Varney VA ,Gaga M ,Jacobson MR ,Durham SR . Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995;50:405-413
CrossRef | Web of Science | Medline6
Dreborg S ,Basomba A ,Belin L , et al. Biological equilibration of allergen preparations: methodological aspects and reproducibility. Clin Allergy 1987;17:537-550
CrossRef | Medline7
Varney VA ,Hamid QA ,Gaga M , et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-651
CrossRef | Web of Science | Medline8
Distribution free methods. In: Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford, England: Blackwell Scientific, 1994:448-68.
9
McKean JW ,Ryan TA . An algorithm for obtaining confidence intervals and point estimates based on ranks in the two sample location problem. ACM Trans Math Software 1977;3:183-185
CrossRef10
Frankland AW ,Augustin R . Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet 1954;1:1055-1057
CrossRef | Web of Science11
McAllen MK . Hyposensitisation in grass pollen hay fever: a double blind trial of alumn precipitated pollen extract and depot emulsion pol-len extract compared with placebo injections. Acta Allergol 1969;24:421-431
Medline12
Ortolani C ,Pastorello E ,Moss RB , et al. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984;73:283-290
CrossRef | Web of Science | Medline13
Bousquet J ,Hejjaoui A ,Skassa-Brociek W , et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987;80:591-598
CrossRef | Web of Science | Medline14
Bousquet J ,Maasch HJ ,Hejjaoui A , et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989;84:546-556
CrossRef | Web of Science | Medline15
Pastorello EA ,Pravettoni V ,Incorvaia C , et al. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever. Allergy 1992;47:281-290
CrossRef | Web of Science | Medline16
Dolz I ,Martinez-Cocera C ,Bartolome JM ,Cimarra M . A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51:489-500
Web of Science | Medline17
Creticos PS ,Reed CE ,Norman PS , et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:501-506
Full Text | Web of Science | Medline18
Abramson MJ ,Puy RM ,Weiner JM . Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;151:969-974
Web of Science | Medline19
Adkinson NF Jr ,Eggleston PA ,Eney D , et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:324-331
Full Text | Web of Science | Medline20
Mosbech H ,Osterballe O . Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988;43:523-529
CrossRef | Web of Science | Medline21
Jacobsen L ,Nuchel Petersen B ,Wihl JA ,Lowenstein H ,Ipsen H . Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997;52:914-920
CrossRef | Web of Science | Medline22
Price JF ,Warner JO ,Hey EN ,Turner MW ,Soothill JF . A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects. Clin Allergy 1984;14:209-219
CrossRef | Medline23
Grammer LC ,Shaughnessy MA ,Suszko IM ,Shaughnessy JJ ,Patterson R . Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol 1984;73:484-489
CrossRef | Web of Science | Medline24
Norman PS ,Creticos PS ,Marsh DG . Frequency of booster injections of allergoids. J Allergy Clin Immunol 1990;85:88-94
CrossRef | Web of Science | Medline25
Des Roches A ,Paradis L ,Knani J , et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51:430-433
Web of Science | Medline26
Naclerio RM ,Proud D ,Moylan B , et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997;100:293-300
CrossRef | Web of Science | Medline27
Imada M ,Simons FE ,Jay FT ,Hayglass KT . Allergen-stimulated interleukin-4 and interferon-gamma production in primary culture: responses of subjects with allergic rhinitis and normal controls. Immunology 1995;85:373-380
Web of Science | Medline28
Till S ,Durham S ,Dickason R , et al. IL-13 production by allergen-stimulated T cells is increased in allergic disease and associated with IL-5 but not IFN-gamma expression. Immunology 1997;91:53-57
CrossRef | Web of Science | Medline29
Kapsenberg ML ,Wierenga EA ,Bos JD ,Jansen HM . Functional subsets of allergen-reactive human CD4+ T cells. Immunol Today 1991;12:392-395
CrossRef | Medline30
Del Prete G ,Maggi E ,Parronchi P , et al. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol 1988;140:4193-4198
Web of Science | Medline31
Punnonen J ,Aversa G ,Cocks BG , et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci U S A 1993;90:3730-3734
CrossRef | Web of Science | Medline32
Lopez AF ,Sanderson CJ ,Gamble JR ,Campbell HD ,Young IG ,Vadas MA . Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988;167:219-224
CrossRef | Web of Science | Medline33
Holgate ST . The mast cell and its function in allergic disease. Clin Exp Allergy 1991;21:Suppl 3:11-16
CrossRef | Web of Science | Medline34
Lichtenstein LM ,Ishizaka K ,Norman PS ,Sobotka AK ,Hill BM . IgE antibody measurements in ragweed hay fever: relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;52:472-482
CrossRef | Web of Science | Medline35
Gleich GJ ,Zimmermann EM ,Henderson LL ,Yunginger JW . Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982;70:261-271
CrossRef | Web of Science | Medline36
Otsuka H ,Mezawa A ,Ohnishi M ,Okubo K ,Seki H ,Okuda M . Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991;21:115-119
CrossRef | Web of Science | Medline37
Creticos PS ,Adkinson NF Jr ,Kagey-Sobotka A , et al. Nasal challenge with ragweed pollen in hay fever patients: effect of immunotherapy. J Clin Invest 1985;76:2247-2253[Erratum, J Clin Invest 1986;78:1421.]
CrossRef | Web of Science | Medline38
Furin MJ ,Norman PS ,Creticos PS , et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1991;88:27-32
CrossRef | Web of Science | Medline39
Rak S ,Lowhagen O ,Venge P . The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988;82:470-480
CrossRef | Web of Science | Medline40
Durham SR ,Ying S ,Varney VA , et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97:1356-1365
CrossRef | Web of Science | Medline41
Hamid QA ,Schotman E ,Jacobson MR ,Walker SM ,Durham SR . Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254-260
CrossRef | Web of Science | Medline42
Secrist H ,Chelen CJ ,Wen Y ,Marshall JD ,Umetsu DT . Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-2130
CrossRef | Web of Science | Medline43
Ebner C ,Siemann U ,Bohle B , et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Ph1 p 1, a major grass pollen allergen. Clin Exp Allergy 1997;27:1007-1015
CrossRef | Web of Science | Medline44
Durham SR ,Till SJ . Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157-164
CrossRef | Web of Science | Medline45
MacGlashan D Jr ,White JM ,Huang SK ,Ono SJ ,Schroeder JT ,Lichtenstein LM . Secretion of IL-4 from human basophils: the relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol 1994;152:3006-3016
Web of Science | Medline46
Bradding P ,Feather IH ,Howarth PH , et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992;176:1381-1386
CrossRef | Web of Science | Medline47
Moqbel R ,Ying S ,Barkans J , et al. Identification of mRNA for interleukin-4 in human eosinophils with granule localization and release of the translated product. J Immunol 1995;155:4939-4947
Web of Science | Medline48
Des Roches A ,Paradis L ,Menardo JL ,Bouges S ,Daures JP ,Bousquet J . Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450-453
CrossRef | Web of Science | Medline
- Citing Articles (375)
Citing Articles
1
Kari C. Nadeau, Arunima Kohli, Shuba Iyengar, Rosemarie H. DeKruyff, Dale T. Umetsu. (2012) Oral Immunotherapy and Anti-IgE Antibody-Adjunctive Treatment for Food Allergy. Immunology and Allergy Clinics of North America 32:1, 111-133
CrossRef2
Chiara Lico, Luca Santi, Richard M. Twyman, Mario Pezzotti, Linda Avesani. (2012) The use of plants for the production of therapeutic human peptides. Plant Cell Reports
CrossRef3
Han-Chih Yuan, Keh-Gong Wu, Chun-Jen Chen, Song-Nan Su, Horng-Der Shen, Yann-Jang Chen, Ho-Jen Peng. (2012) Mapping of IgE and IgG<sub>4</sub> Antibody-Binding Epitopes in Cyn d 1, the Major Allergen of Bermuda Grass Pollen. International Archives of Allergy and Immunology 157:2, 125-135
CrossRef4
Roberta Alesina, Massimo Milani, Silvia Pecora. (2012) A Multicenter, Randomized, Parallel-Group Trial Assessing Compliance, Tolerability, Safety, and Efficacy to Treatment with Grass Allergy Tablets in 261 Patients with Grass Pollen Rhinoconjunctivitis. Journal of Allergy 2012, 1-6
CrossRef5
Lucie Mondoulet, Vincent Dioszeghy, Mélanie Ligouis, Véronique Dhelft, Emilie Puteaux, Christophe Dupont, Pierre-Henri Benhamou. (2012) Epicutaneous Immunotherapy Compared with Sublingual Immunotherapy in Mice Sensitized to Pollen (Phleum pratense). ISRN Allergy 2012, 1-8
CrossRef6
M. Calderón, V. Cardona, P. Demoly. (2012) One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions. Allergyn/a
CrossRef7
David J. Fitzhugh, Richard F. Lockey. (2011) Allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology 11:6, 554-559
CrossRef8
Aarif O. Eifan, Mohamed H. Shamji, Stephen R. Durham. (2011) Long-term clinical and immunological effects of allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology 11:6, 586-593
CrossRef9
Kayo Ohkouchi, Seiji Kawamoto, Kenji Tatsugawa, Noboru Yoshikawa, Yuki Takaoka, Sayumi Miyauchi, Tsunehiro Aki, Mitsuo Yamashita, Yoshikatsu Murooka, Kazuhisa Ono. (2011) Prophylactic effect of Lactobacillus oral vaccine expressing a Japanese cedar pollen allergen. Journal of Bioscience and Bioengineering
CrossRef10
Salvatore Tripodi, Tullio Frediani, Sandra Lucarelli, Francesco Macrì, Giuseppe Pingitore, Andrea Di Rienzo Businco, Arianna Dondi, Paola Pansa, Giovanni Ragusa, Riccardo Asero, Diego Faggian, Mario Plebani, Paolo Maria Matricardi. (2011) Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: Implications for specific immunotherapy. Journal of Allergy and Clinical Immunology
CrossRef11
En-Chih Liao, Jaw-Ji Tsai. (2011) Clinical Effectiveness of Tyrophagus putrescentiae Allergy by Local Nasal Immunotherapy Using Strips of Dermatophagoides pteronyssinus. Journal of Asthma 48:9, 957-964
CrossRef12
Harold S. Nelson. (2011) Some highlights of the first century of immunotherapy. Annals of Allergy, Asthma & Immunology 107:5, 417-421
CrossRef13
Giovanni Passalacqua. (2011) Specific immunotherapy: beyond the clinical scores. Annals of Allergy, Asthma & Immunology 107:5, 401-406
CrossRef14
Birgit Linhart, Rudolf Valenta. (2011) Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine
CrossRef15
O. Pfaar, Z. Urry, D. S. Robinson, A. Sager, D. Richards, C. M. Hawrylowicz, M. Bräutigam, L. Klimek. (2011) A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy*. Allergyno-no
CrossRef16
M. H. Shamji, C. Ljørring, J. N. Francis, M. A Calderon, M. Larché, I. Kimber, A. J. Frew, H. Ipsen, K. Lund, P. A. Würtzen, S. R. Durham. (2011) Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergyno-no
CrossRef17
Wei Zhao, Gregorio Gomez, Matthew Macey, Christopher L. Kepley, Lawrence B. Schwartz. (2011) In Vitro Desensitization of Human Skin Mast Cells. Journal of Clinical Immunology
CrossRef18
Eszter Fodor, Edina Garaczi, Hilda Polyánka, Andrea Koreck, Lajos Kemény, Márta Széll. (2011) The rs3761548 polymorphism of FOXP3 is a protective genetic factor against allergic rhinitis in the Hungarian female population. Human Immunology 72:10, 926-929
CrossRef19
Erik Wambre, Jonathan H. DeLong, Eddie A. James, Rebecca E. LaFond, David Robinson, William W. Kwok. (2011) Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. Journal of Allergy and Clinical Immunology
CrossRef20
M. H. Shamji, S. R. Durham. (2011) Mechanisms of immunotherapy to aeroallergens. Clinical & Experimental Allergy 41:9, 1235-1246
CrossRef21
L. Klimek, J. Willers, A. Hammann-Haenni, O. Pfaar, H. Stocker, P. Mueller, W. A. Renner, M. F. Bachmann. (2011) Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clinical & Experimental Allergy 41:9, 1305-1312
CrossRef22
A. J. Frew. (2011) Hundred years of allergen immunotherapy. Clinical & Experimental Allergy 41:9, 1221-1225
CrossRef23
Tania Mucci, Satish Govindaraj, Jody Tversky. (2011) Allergic Rhinitis. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:5, 634-644
CrossRef24
S. M. Walker, S. R. Durham, S. J. Till, G. Roberts, C. J. Corrigan, S. C. Leech, M. T. Krishna, R. K. Rajakulasingham, A. Williams, J. Chantrell, L. Dixon, A. J. Frew, S. M. Nasser. (2011) Immunotherapy for allergic rhinitis. Clinical & Experimental Allergy 41:9, 1177-1200
CrossRef25
E. Gadermaier, J. Staikuniene, S. Scheiblhofer, J. Thalhamer, M. Kundi, K. Westritschnig, I. Swoboda, S. Flicker, R. Valenta. (2011) Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation. Allergy 66:9, 1174-1182
CrossRef26
Whitney W. Stevens, Larry Borish, John W. Steinke. 2011. Interleukin 10. , 215-224.
CrossRef27
Melina Makatsori, Stephen Durham, Moises A Calderon, Moises A Calderon. 2011. Specific immunotherapy for latex allergy. .
CrossRef28
Linda Cox, Dana Wallace. (2011) Specific Allergy Immunotherapy for Allergic Rhinitis: Subcutaneous and Sublingual. Immunology and Allergy Clinics of North America 31:3, 561-599
CrossRef29
J.O. Warner. (2011) Immunotherapy in asthma. Paediatrics and Child Health 21:7, 329-330
CrossRef30
S. R. Durham, . (2011) Sustained effects of grass pollen AIT. Allergy 66, 50-52
CrossRef31
Sandra Y. Lin, Bryan Leatherman. (2011) Sublingual Immunotherapy. Otolaryngologic Clinics of North America 44:3, 753-764
CrossRef32
D. Moldaver, M. Larché. (2011) Immunotherapy with peptides. Allergy 66:6, 784-791
CrossRef33
S. Radulovic, D. Wilson, M. Calderon, S. Durham. (2011) Systematic reviews of sublingual immunotherapy (SLIT). Allergy 66:6, 740-752
CrossRef34
Yekaterina A. Koshkareva, John H. Krouse. (2011) Immunotherapy – Traditional. Otolaryngologic Clinics of North America 44:3, 741-752
CrossRef35
R. Valenta, B. Linhart, I. Swoboda, V. Niederberger. (2011) Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 66:6, 775-783
CrossRef36
Katarzyna Niespodziana, Margarete Focke-Tejkl, Birgit Linhart, Vera Civaj, Katharina Blatt, Peter Valent, Marianne van Hage, Hans Grönlund, Rudolf Valenta. (2011) A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS. Journal of Allergy and Clinical Immunology 127:6, 1562-1570.e6
CrossRef37
M. Jutel, C. A. Akdis. (2011) Immunological mechanisms of allergen-specific immunotherapy. Allergy 66:6, 725-732
CrossRef38
J. David Osguthorpe. (2011) The Evolution of Understanding Inhalant Allergy. Otolaryngologic Clinics of North America 44:3, 519-535
CrossRef39
Stephen R. Durham, Harold Nelson. (2011) Allergen Immunotherapy: A Centenary Celebration. World Allergy Organization Journal 4:6, 104-106
CrossRef40
M. V. Kopp. (2011) Role of immunmodulators in allergen-specific immunotherapy. Allergy 66:6, 792-797
CrossRef41
Guy Scadding, Stephen R. Durham. (2011) Mechanisms of Sublingual Immunotherapy. Immunology and Allergy Clinics of North America 31:2, 191-209
CrossRef42
Harold S. Nelson. (2011) Subcutaneous Injection Immunotherapy for Optimal Effectiveness. Immunology and Allergy Clinics of North America 31:2, 211-226
CrossRef43
Zuojia Chen, Fang Lin, Yayi Gao, Zhiyuan Li, Jing Zhang, Yue Xing, Zihou Deng, Zhengju Yao, Andy Tsun, Bin Li. (2011) FOXP3 and RORγt: Transcriptional regulation of Treg and Th17. International Immunopharmacology 11:5, 536-542
CrossRef44
David J. Fitzhugh, Richard F. Lockey. (2011) History of Immunotherapy: The First 100 Years. Immunology and Allergy Clinics of North America 31:2, 149-157
CrossRef45
Mohamed H. Shamji, Louisa K. James, Stephen R. Durham. (2011) Serum Immunologic Markers for Monitoring Allergen-Specific Immunotherapy. Immunology and Allergy Clinics of North America 31:2, 311-323
CrossRef46
Mark Larché. (2011) Peptide and Recombinant Immunotherapy. Immunology and Allergy Clinics of North America 31:2, 377-389
CrossRef47
Philippe Moingeon, Vincent Lombardi, Nathalie Saint-Lu, Sophie Tourdot, Véronique Bodo, Laurent Mascarell. (2011) Adjuvants and Vector Systems for Allergy Vaccines. Immunology and Allergy Clinics of North America 31:2, 407-419
CrossRef48
H. Gozde Kanmaz, K. Harmanci, C. Razi, G. Kose, M.R. Cengizlier. (2011) Specific immunotherapy improves asthma related quality of life in childhood. Allergologia et Immunopathologia 39:2, 68-72
CrossRef49
M. T. Krishna, A. P. Huissoon. (2011) Clinical immunology review series: an approach to desensitization. Clinical & Experimental Immunology 163:2, 131-146
CrossRef50
Reginaldo A. Trindade, Pedro K. Kiyohara, Pedro S. de Araujo, Maria H. Bueno da Costa. (2011) PLGA microspheres containing bee venom proteins for preventive immunotherapy. International Journal of Pharmaceutics
CrossRef51
William Moote, Harold Kim. (2011) Allergen-specific immunotherapy. Allergy, Asthma & Clinical Immunology 7:Suppl 1, S5
CrossRef52
Fridolin Groß, Gerhard Metzner, Ulrich Behn. (2011) Mathematical modeling of allergy and specific immunotherapy: Th1–Th2–Treg interactions. Journal of Theoretical Biology 269:1, 70-78
CrossRef53
C. Pellaton-Longaretti, C. Boudousquie, N. Barbier, C. Barbey, C. B. Argiroffo, Y. Donati, A. Sauty, F. Spertini. (2011) CD4+CD25-mTGF + T cells induced by nasal application of ovalbumin transfer tolerance in a therapeutic model of asthma. International Immunology 23:1, 17-27
CrossRef54
SHIGETOSHI HORIGUCHI. (2011) Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology 25:1, 24-29
CrossRef55
Letty A de Weger, Thijs Beerthuizen, Jeannette M Gast-Strookman, Dirk T van der Plas, Ingrid Terreehorst, Pieter S Hiemstra, Jacob K Sont. (2011) Difference in symptom severity between early and late grass pollen season in patients with seasonal allergic rhinitis. Clinical and Translational Allergy 1:1, 18
CrossRef56
O. Pfaar, D. S. Robinson, A. Sager, R. Emuzyte. (2010) Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy 65:12, 1614-1621
CrossRef57
C. Barth, F. Anero, O. Pfaar, L. Klimek, K. Hörmann, B. A. Stuck. (2010) Safety aspects of subcutaneous immunotherapy with multiple allergens—a retrospective analysis on polysensitized patients. European Archives of Oto-Rhino-Laryngology 267:12, 1873-1879
CrossRef58
Douglas S. Robinson. (2010) The role of the T cell in asthma. Journal of Allergy and Clinical Immunology 126:6, 1081-1091
CrossRef59
Gabriela Senti, Andreas U Freiburghaus, Thomas M Kundig. (2010) Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials. Current Opinion in Allergy and Clinical Immunology 10:6, 582-586
CrossRef60
Ebrahim M. Shakir, Dorothy S. Cheung, Mitchell H. Grayson. (2010) Mechanisms of immunotherapy: a historical perspective. Annals of Allergy, Asthma & Immunology 105:5, 340-347
CrossRef61
Maurizio Marogna, Igino Spadolini, Alessandro Massolo, Giorgio Walter Canonica, Giovanni Passalacqua. (2010) Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. Journal of Allergy and Clinical Immunology 126:5, 969-975
CrossRef62
Ira Finegold, Robert J. Dockhorn, Daniel Ein, William K. Dolen, John Oppenheimer, Lawrence H. Potter. (2010) Immunotherapy throughout the decades: from Noon to now. Annals of Allergy, Asthma & Immunology 105:5, 328-336
CrossRef63
Jeffrey A. Bluestone, Hugh Auchincloss, Gerald T. Nepom, Daniel Rotrosen, E. William St. Clair, Laurence A. Turka. (2010) The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nature Reviews Immunology 10:11, 797-803
CrossRef64
Moises A Calderon, Robert J Boyle, Helen Nankervis, Ignacio García Núñez, Hywel C Williams, Stephen Durham, Moises A Calderon. 2010. Specific allergen immunotherapy for the treatment of atopic eczema. .
CrossRef65
Moises A Calderon, Bernadette Alves, Mikila Jacobson, Brian Hurwitz, Aziz Sheikh, Stephen Durham. (2010) Cochrane review: Allergen injection immunotherapy for seasonal allergic rhinitis. Evidence-Based Child Health: A Cochrane Review Journal 5:3, 1279-1379
CrossRef66
Guiseppina Rotiroti, Glenis Scadding. (2010) Commentary on ‘Cochrane Meta-Analysis of Subcutaneous Immunotherapy for Allergic Rhinitis’. Evidence-Based Child Health: A Cochrane Review Journal 5:3, 1382-1384
CrossRef67
Vitaly Vasilevko, Viorela Pop, Hyun Jin Kim, Tommy Saing, Charles C. Glabe, Saskia Milton, Edward G. Barrett, Carl W. Cotman, David H. Cribbs, Elizabeth Head. (2010) Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiology of Disease 39:3, 301-310
CrossRef68
Michael J Abramson, Robert M Puy, John M Weiner, Michael J Abramson. 2010. Injection allergen immunotherapy for asthma. .
CrossRef69
A.-S. Höiby, V. Strand, D.S. Robinson, A. Sager, S. Rak. (2010) Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid® birch pollen extract: a randomized, double-blind, placebo-controlled study. Clinical & Experimental Allergy 40:7, 1062-1070
CrossRef70
C M Lloyd, J R Murdoch. (2010) Tolerizing allergic responses in the lung. Mucosal Immunology 3:4, 334-344
CrossRef71
Andrew Bush. (2010) The problem of preschool wheeze: new developments, new questions. Acta medica Lituanica 17:1, 40-50
CrossRef72
M. Rosewich, J. Schulze, O. Eickmeier, T. Telles, M. A. Rose, R. Schubert, S. Zielen. (2010) Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clinical & Experimental Immunology 160:3, 403-410
CrossRef73
E. Maggi. (2010) T cell responses induced by allergen-specific immunotherapy. Clinical & Experimental Immunologyno-no
CrossRef74
M. Calderon, R. Mösges, M. Hellmich, P. Demoly. (2010) Towards evidence-based medicine in specific grass pollen immunotherapy. Allergy 65:4, 420-434
CrossRef75
Rudolf Valenta, Fatima Ferreira, Margarete Focke-Tejkl, Birgit Linhart, Verena Niederberger, Ines Swoboda, Susanne Vrtala. (2010) From Allergen Genes to Allergy Vaccines. Annual Review of Immunology 28:1, 211-241
CrossRef76
Linda Cox, Desiree Larenas-Linnemann, Richard F. Lockey, Giovanni Passalacqua. (2010) Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. Journal of Allergy and Clinical Immunology 125:3, 569-574.e7
CrossRef77
Wolfgang Kamin, Matthias Volkmar Kopp, Frank Erdnuess, Uwe Schauer, Stefan Zielen, Ulrich Wahn. (2010) Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatric Allergy and Immunology 21:1-Part-II, e160-e165
CrossRef78
Klaus J. Erb, Domnic H. Martyres, Peter Seither. 2010. Antiasthmatic Agents. .
CrossRef79
Kimihiro Okubo. (2010) Evidence of Allergen Immunotherapy for Allergic Rhinitis. Practica Oto-Rhino-Laryngologica 103:8, 695-700
CrossRef80
Terri F Brown-Whitehorn, Jonathan M Spergel. (2010) The link between allergies and eosinophilic esophagitis: implications for management strategies. Expert Review of Clinical Immunology 6:1, 101-109
CrossRef81
Naoka Itoh, Yasuharu Itagaki, Kazuyuki Kurihara. (2010) Rush Specific Oral Tolerance Induction in School-Age Children with Severe Egg Allergy: One Year Follow Up. Allergology International 59:1, 43-51
CrossRef82
Kimihiro Okubo, Minoru Gotoh. (2010) Allergen Immunotherapy for Allergic Rhinitis. Journal of Nippon Medical School 77:6, 285-289
CrossRef83
Hitomi Ogihara, Atsushi Yuta, Yukiko Miyamoto, Satoko Usui, Kazuhiko Takeuchi. (2010) The Efficacy of Allergen-specific Subcutaneous Immunotherapy for Japanese Cedar Pollinosis. Practica Oto-Rhino-Laryngologica 103:3, 215-220
CrossRef84
Stephen R. Durham, Waltraud Emminger, Alexander Kapp, Giselda Colombo, Jan G.R. de Monchy, Sabina Rak, Glenis K. Scadding, Jens S. Andersen, Bente Riis, Ronald Dahl. (2010) Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. Journal of Allergy and Clinical Immunology 125:1, 131-138.e7
CrossRef85
Karin Dam Petersen, Dorte Gyrd-Hansen, Allan Linneberg, Ronald Dahl, Jørgen Nedergaard Larsen, Henning Løwenstein, Christian Kronborg. (2010) Willingness to pay for allergy-vaccination among Danish patients with respiratory allergy. International Journal of Technology Assessment in Health Care 26:01, 20
CrossRef86
Cheryl S. Hankin, Linda Cox, David Lang, Amy Bronstone, Paul Fass, Bryan Leatherman, Zhaohui Wang. (2010) Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Annals of Allergy, Asthma & Immunology 104:1, 79-85
CrossRef87
Jörg Kleine-Tebbe, Gerald Hanf, Dietmar A. Herold. (2009) Update zur spezifischen Immuntherapie (SIT) bei allergischer Rhinokonjunktivitis: Subkutane (SCIT) und sublinguale Applikation (SLIT) der Hyposensibilisierung. Journal für Verbraucherschutz und Lebensmittelsicherheit 4:S2, 33-40
CrossRef88
Gabriela Senti, Pål Johansen, Thomas M Kündig. (2009) Intralymphatic immunotherapy. Current Opinion in Allergy and Clinical Immunology 9:6, 537-543
CrossRef89
Gianenrico Senna, Erminia Ridolo, Moises Calderon, Carlo Lombardi, Giorgio W Canonica, Giovanni Passalacqua. (2009) Evidence of adherence to allergen-specific immunotherapy. Current Opinion in Allergy and Clinical Immunology 9:6, 544-548
CrossRef90
&NA;. (2009) CHAPTER 6: IMPACT OF SUBLINGUAL IMMUNOTHERAPY ON THE NATURAL HISTORY OF RESPIRATORY ALLERGY. World Allergy Organization Journal 2:11, 261-263
CrossRef91
Franca Acquistapace, Fabio Agostinis, Vincenzo Castella, Ahmad Kantar, Elio Novembre, Maria Rosaria Perrone, Michele Pietrasanta, Renato Sambugaro, Massimo Milani. (2009) Efficacy of sublingual specific immunotherapy in intermittent and persistent allergic rhinitis in children: an observational case-control study on 171 patients. The EFESO-children Multicenter Trial. Pediatric Allergy and Immunology 20:7, 660-664
CrossRef92
&NA;. (2009) CHAPTER 2: ALLERGEN SPECIFIC IMMUNOTHERAPY. World Allergy Organization Journal 2:11, 239-242
CrossRef93
Milan Buc, Martin Dzurilla, Mojmir Vrlik, Maria Bucova. (2009) Immunopathogenesis of bronchial asthma. Archivum Immunologiae et Therapiae Experimentalis 57:5, 331-344
CrossRef94
Deepsikha Srivastava, Naveen Arora, Bhanu Pratap Singh. (2009) Current immunological approaches for management of allergic rhinitis and bronchial asthma. Inflammation Research 58:9, 523-536
CrossRef95
(2009) Treating allergy: where to from here?. Internal Medicine Journal 39:8, 491-494
CrossRef96
Mübeccel Akdis, Cezmi A. Akdis. (2009) Therapeutic manipulation of immune tolerance in allergic disease. Nature Reviews Drug Discovery 8:8, 645-660
CrossRef97
Nicole Wopfner, Beatrice Jahn-Schmid, Georg Schmidt, Tanja Christ, Gudrun Hubinger, Peter Briza, Christian Radauer, Barbara Bohle, Lothar Vogel, Christof Ebner, Riccardo Asero, Fatima Ferreira, Robert Schwarzenbacher. (2009) The alpha and beta subchain of Amb a 1, the major ragweed-pollen allergen show divergent reactivity at the IgE and T-cell level. Molecular Immunology 46:10, 2090-2097
CrossRef98
Dean Tey, Ralf G Heine. (2009) Egg allergy in childhood: an update. Current Opinion in Allergy and Clinical Immunology 9:3, 244-250
CrossRef99
Anaïs Pipet, Karine Botturi, Domitille Pinot, Daniel Vervloet, Antoine Magnan. (2009) Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy. Respiratory Medicine 103:6, 800-812
CrossRef100
J R Nichani, J de Carpentier. (2009) Safety of sublingual grass pollen immunotherapy after anaphylaxis. The Journal of Laryngology & Otology 123:06, 683
CrossRef101
Jaymin B Morjaria, Riccardo Polosa. (2009) Off-label use of omalizumab in non-asthma conditions: new opportunities. Expert Review of Respiratory Medicine 3:3, 299-308
CrossRef102
Harold S. Nelson. (2009) Multiallergen immunotherapy for allergic rhinitis and asthma. Journal of Allergy and Clinical Immunology 123:4, 763-769
CrossRef103
Cezmi A. Akdis, Mübeccel Akdis. (2009) Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. Journal of Allergy and Clinical Immunology 123:4, 735-746
CrossRef104
Christine Loewenstein, Ralf S. Mueller. (2009) A review of allergen-specific immunotherapy in human and veterinary medicine. Veterinary Dermatology 20:2, 84-98
CrossRef105
Makoto Miyara, Kajsa Wing, Shimon Sakaguchi. (2009) Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. Journal of Allergy and Clinical Immunology 123:4, 749-755
CrossRef106
Jennifer M. Rolland, Leanne M. Gardner, Robyn E. O'Hehir. (2009) Allergen-related approaches to immunotherapy. Pharmacology & Therapeutics 121:3, 273-284
CrossRef107
A. Morris. (2009) Atopy, anamnesis and allergy testing. InnovAiT 2:3, 158-165
CrossRef108
David H. Broide. (2009) Immunomodulation of Allergic Disease. Annual Review of Medicine 60:1, 279-291
CrossRef109
Ad Jansen, Kristian Funding Andersen, Harald Brüning. (2009) Evaluation of a compliance device in a subgroup of adult patients receiving specific immunotherapy with grass allergen tablets (GRAZAX®) in a randomized, open-label, controlled study: An a priori subgroup analysis. Clinical Therapeutics 31:2, 321-327
CrossRef110
François Spertini, Christophe Reymond, Annette Leimgruber. (2009) Allergen-specific immunotherapy of allergy and asthma: current and future trends. Expert Review of Respiratory Medicine 3:1, 37-51
CrossRef111
Paula J Busse, Kiran Kilaru. (2009) Complexities of Diagnosis and Treatment of Allergic Respiratory Disease in the Elderly. Drugs & Aging 26:1, 1-22
CrossRef112
Hyo-Bin Kim, Hyun-Seung Jin, So-Yeon Lee, Ja-Hyeong Kim, Bong-Seong Kim, Seong Jong Park, Soo-Jong Hong. (2009) The Effect of Rush Immunotherapy with House Dust Mite in the Production of IL-5 and IFN-γ from the Peripheral Blood T Cells of Asthmatic Children. Journal of Korean Medical Science 24:3, 392
CrossRef113
Takao Fujisawa, Mizuho Nagao, Yukiko Hiraguchi, Koa Hosoki, Reiko Tokuda, Satoko Usui, Sawako Masuda, Makito Shinoda, Akihiko Hashiguchi, Masao Yamaguchi. (2009) Biomarkers for Allergen Immunotherapy in Cedar Pollinosis. Allergology International 58:2, 163-170
CrossRef114
Maurizio Marogna, Igino Spadolini, Alessandro Massolo, Daniele Berra, Pietro Zanon, Elena Chiodini, Giorgio Walter Canonica, Giovanni Passalacqua. (2009) Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due tograss pollen. Annals of Allergy, Asthma & Immunology 102:1, 69-75
CrossRef115
(2009) GEMA (Guía española del manejo del asma). Archivos de Bronconeumología 45, 2-35
CrossRef116
Dragana Stanic, Lidija Burazer, Marija Gavrovic-Jankulovic, Ratko Jankov, Tanja Cirkovic-Velickovic. (2009) Chemical modification of Art v 1, a major mugwort pollen allergen, by cis-aconitylation and citraconylation. Journal of the Serbian Chemical Society 74:4, 359-366
CrossRef117
Roy Gerth van Wijk. (2008) When to initiate immunotherapy in children with allergic disease? Lessons from the paediatric studies. Current Opinion in Allergy and Clinical Immunology 8:6, 565-570
CrossRef118
S. Nasser, U. Vestenbaek, A. Beriot-Mathiot, P. B. Poulsen. (2008) Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 63:12, 1624-1629
CrossRef119
Stephen R Durham. (2008) Sublingual immunotherapy: what have we learnt from the ‘big trials’?. Current Opinion in Allergy and Clinical Immunology 8:6, 577-584
CrossRef120
G. Senti, B. M. Prinz Vavricka, I. Erdmann, M. I. Diaz, R. Markus, S. J. McCormack, J. J. Simard, B. Wuthrich, R. Crameri, N. Graf, P. Johansen, T. M. Kundig. (2008) Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proceedings of the National Academy of Sciences 105:46, 17908-17912
CrossRef121
J. O. Warner. (2008) A century of immunotherapy. Pediatric Allergy and Immunology 19:7, 569-570
CrossRef122
Sara Gómez, Carlos Gamazo, Beatriz San Roman, Marta Ferrer, Maria Luisa Sanz, Socorro Espuelas, Juan M. Irache. (2008) Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis. European Journal of Pharmaceutics and Biopharmaceutics 70:3, 711-717
CrossRef123
A. M. Russano, E. Agea, C. Casciari, F. M. de Benedictis, F. Spinozzi. (2008) Complementary roles for lipid and protein allergens in triggering innate and adaptive immune systems. Allergy 63:11, 1428-1437
CrossRef124
Isabelle Tillie-Leblond, Antoine Magnan, Gabrielle Pauli, Daniel Vervloet, Benoît Wallaert, Alain Didier, Jacques Ameille, Philippe Godard, the group of experts. (2008) Asthma and allergy: Short texts and recommendations of the expert conference of the French Speaking Pneumology Society (SPLF), in partnership with the French Society of Allergology and Clinical Immunology (SFAIC), the French Society of Occupational Medicine (SFMT) and the “Asthma–Allergy” association. Respiratory Medicine 102:10, 1483-1493
CrossRef125
Massimo Milani, Silvia Pecora, Samuele Burastero. (2008) Observational study of sublingual specific immunotherapy in persistent and intermittent allergic rhinitis: the EFESO trial. Current Medical Research and Opinion 24:9, 2719-2724
CrossRef126
Susanne Halken, Susanne Lau, Erkka Valovirta. (2008) New visions in specific immunotherapy in children: an iPAC summary and future trends. Pediatric Allergy and Immunology 19, 60-70
CrossRef127
Birgit Linhart, Nadine Mothes-Luksch, Susanne Vrtala, Michael Kneidinger, Peter Valent, Rudolf Valenta. (2008) A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biological Chemistry 389:7, 925-933
CrossRef128
J. M. Rolland, R. E. O'Hehir. (2008) Latex allergy: a model for therapy. Clinical & Experimental Allergy 38:6, 898-912
CrossRef129
Robert E. Esch, Robert K. Bush, David Peden, Richard F. Lockey. (2008) Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Annals of Allergy, Asthma & Immunology 100:5, 475-481
CrossRef130
Cristina Antúnez, Cristobalina Mayorga, José Luis Corzo, Antonio Jurado, María José Torres. (2008) Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration. Pediatric Allergy and Immunology 19:3, 210-218
CrossRef131
Esther Röder, Marjolein Y. Berger, Hans de Groot, Roy Gerth van Wijk. (2008) Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatric Allergy and Immunology 19:3, 197-207
CrossRef132
James N. Francis, Louisa K. James, Giannis Paraskevopoulos, Cheukyee Wong, Moises A. Calderon, Stephen R. Durham, Stephen J. Till. (2008) Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. Journal of Allergy and Clinical Immunology 121:5, 1120-1125.e2
CrossRef133
Moises A Calderon, Vicky A Carr, Mikila Jacobson, Aziz Sheikh, Stephen Durham, Moises A Calderon. 2008. Allergen injection immunotherapy for perennial allergic rhinitis. .
CrossRef134
J. Bousquet, N. Khaltaev, A. A. Cruz, J. Denburg, W. J. Fokkens, A. Togias, T. Zuberbier, C. E. Baena-Cagnani, G. W. Canonica, C. Van Weel, I. Agache, N. Aït-Khaled, C. Bachert, M. S. Blaiss, S. Bonini, L.-P. Boulet, P.-J. Bousquet, P. Camargos, K.-H. Carlsen, Y. Chen, A. Custovic, R. Dahl, P. Demoly, H. Douagui, S. R. Durham, R. Gerth Van Wijk, O. Kalayci, M. A. Kaliner, Y.-Y. Kim, M. L. Kowalski, P. Kuna, L. T. T. Le, C. Lemiere, J. Li, R. F. Lockey, S. Mavale-Manuel, E. O. Meltzer, Y. Mohammad, J. Mullol, R. Naclerio, R. E. O’Hehir, K. Ohta, S. Ouedraogo, S. Palkonen, N. Papadopoulos, G. Passalacqua, R. Pawankar, T. A. Popov, K. F. Rabe, J. Rosado-Pinto, G. K. Scadding, F. E. R. Simons, E. Toskala, E. Valovirta, P. Van Cauwenberge, D.-Y. Wang, M. Wickman, B. P. Yawn, A. Yorgancioglu, O. M. Yusuf, H. Zar, I. Annesi-Maesano, E. D. Bateman, A. Ben Kheder, D. A. Boakye, J. Bouchard, P. Burney, W. W. Busse, M. Chan-Yeung, N. H. Chavannes, A. Chuchalin, W. K. Dolen, R. Emuzyte, L. Grouse, M. Humbert, C. Jackson, S. L. Johnston, P. K. Keith, J. P. Kemp, J.-M. Klossek, D. Larenas-Linnemann, B. Lipworth, J.-L. Malo, G. D. Marshall, C. Naspitz, K. Nekam, B. Niggemann, E. Nizankowska-Mogilnicka, Y. Okamoto, M. P. Orru, P. Potter, D. Price, S. W. Stoloff, O. Vandenplas, G. Viegi, D. Williams. (2008) Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. Allergy 63, 8-160
CrossRef135
Linda Cox. (2008) Sublingual immunotherapy and allergic rhinitis. Current Allergy and Asthma Reports 8:2, 102-110
CrossRef136
Oliver Pfaar, Ludger Klimek. (2008) Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Annals of Allergy, Asthma & Immunology 100:3, 256-263
CrossRef137
I Leonard Bernstein, James T. Li, David I. Bernstein, Robert Hamilton, Sheldon L. Spector, Ricardo Tan, Scott Sicherer, David B.K. Golden, David A. Khan, Richard A. Nicklas, Jay M. Portnoy, Joann Blessing-Moore, Linda Cox, David M. Lang, John Oppenheimer, Christopher C. Randolph, Diane E. Schuller, Stephen A. Tilles, Dana V. Wallace, Estelle Levetin, Richard Weber. (2008) Allergy Diagnostic Testing: An Updated Practice Parameter. Annals of Allergy, Asthma & Immunology 100:3, S1-S148
CrossRef138
Stephen T. Holgate, Riccardo Polosa. (2008) Treatment strategies for allergy and asthma. Nature Reviews Immunology 8:3, 218-230
CrossRef139
Roy Gerth van Wijk. (2008) Sublingual immunotherapy in children. Expert Opinion on Biological Therapy 8:3, 291-298
CrossRef140
Ronald Dahl, Alexander Kapp, Giselda Colombo, Jan G.R. de Monchy, Sabina Rak, Waltraud Emminger, Bente Riis, Pernille M. Grønager, Stephen R. Durham. (2008) Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. Journal of Allergy and Clinical Immunology 121:2, 512-518.e2
CrossRef141
Anthony J. Frew. 2008. Immunotherapy of allergic disease. , 1383-1391.
CrossRef142
Cheryl S. Hankin, Linda Cox, David Lang, Arthur Levin, Gary Gross, Gene Eavy, Eli Meltzer, Doug Burgoyne, Amy Bronstone, Zhaohui Wang. (2008) Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: Patterns of care, resource use, and costs. Journal of Allergy and Clinical Immunology 121:1, 227-232
CrossRef143
Christian Möbs, Caroline Slotosch, Harald Löffler, Wolfgang Pfützner, Michael Hertl. (2008) Cellular and Humoral Mechanisms of Immune Tolerance in Immediate-Type Allergy Induced by Specific Immunotherapy. International Archives of Allergy and Immunology 147:3, 171-178
CrossRef144
G. Willer, G. Menz. (2008) Update Allergologie. Der Pneumologe 5:1, 16-23
CrossRef145
Eva G. Marazuela, Rosalía Rodríguez, Héctor Fernández-García, Mª Soledad García, Mayte Villalba, Eva Batanero. (2008) Intranasal immunization with a dominant T-cell epitope peptide of a major allergen of olive pollen prevents mice from sensitization to the whole allergen. Molecular Immunology 45:2, 438-445
CrossRef146
Kimihiro Okubo, Minoru Gotoh, Shigeharu Fujieda, Mitsuhiro Okano, Hirokazu Yoshida, Hiroshi Morikawa, Keisuke Masuyama, Yoshitaka Okamoto, Makoto Kobayashi. (2008) A Randomized Double-Blind Comparative Study of Sublingual Immunotherapy for Cedar Pollinosis. Allergology International 57:3, 265-275
CrossRef147
Ayako Kawakami, Rikiya Koketsu, Maho Suzukawa, Mizuho Nagao, Yukiko Hiraguchi, Reiko Tokuda, Takao Fujisawa, Hiroyuki Nagase, Ken Ohta, Kazuhiko Yamamoto, Masao Yamaguchi. (2008) Blocking Antibody Is Generated in Allergic Rhinitis Patients during Specific Immunotherapy Using Standardized Japanese Cedar Pollen Extract. International Archives of Allergy and Immunology 146:1, 54-60
CrossRef148
G. K. Scadding, S. R. Durham, R. Mirakian, N. S. Jones, S. C. Leech, S. Farooque, D. Ryan, S. M. Walker, A. T. Clark, T. A. Dixon, S. R. A. Jolles, N. Siddique, P. Cullinan, P. H. Howarth, S. M. Nasser. (2008) BSACI guidelines for the management of allergic and non-allergic rhinitis. Clinical & Experimental Allergy 38:1, 19-42
CrossRef149
Inal Ali, Keskin Goksal, Baysal Ozan, Duman Gulsen. (2008) Long-term allergen-specific immunotherapy correlates with long-term allergen-specific immunological tolerance. Advances in Therapy 25:1, 29-36
CrossRef150
L. B. Bacharier, A. Boner, K.-H. Carlsen, P. A. Eigenmann, T. Frischer, M. Götz, P. J. Helms, J. Hunt, A. Liu, N. Papadopoulos, T. Platts-Mills, P. Pohunek, F. E. R. Simons, E. Valovirta, U. Wahn, J. Wildhaber, . (2008) Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 63:1, 5-34
CrossRef151
Mary Dell Railey, Margaret A. Adair, A. Wesley Burks. (2008) Allergen immunotherapy for allergic rhinitis. Current Allergy and Asthma Reports 8:1, 1-3
CrossRef152
Paul A. Greenberger, Mark Ballow, Thomas B. Casale, Thomas A.E. Platts-Mills, Hugh A. Sampson. (2007) Sublingual immunotherapy and subcutaneous immunotherapy: Issues in the United States. Journal of Allergy and Clinical Immunology 120:6, 1466-1468
CrossRef153
Linda Cox. (2007) Sublingual immunotherapy in pediatric allergic rhinitis and asthma: Efficacy, safety, and practical considerations. Current Allergy and Asthma Reports 7:6, 410-420
CrossRef154
A. Didier, F. de Blay, L. Tetu, J.C. Dubus, A. Grimfeld, J. Just, P. Demoly. (2007) Existe-t-il des traitements spécifiques pour l’asthmatique allergique ?. Revue des Maladies Respiratoires 24:8, 41-51
CrossRef155
Maria Dolores Ibañez, Friedrich Kaiser, Roland Knecht, Alicia Armentia, Helmut Schöpfer, Bente Tholstrup, Albrecht Bufe. (2007) Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatric Allergy and Immunology 18:6, 516-522
CrossRef156
Sven Klunker, Lavina R. Saggar, Vicki Seyfert-Margolis, Adam L. Asare, Thomas B. Casale, Stephen R. Durham, James N. Francis. (2007) Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. Journal of Allergy and Clinical Immunology 120:3, 688-695
CrossRef157
G.W. Canonica, P.B. Poulsen, U. Vestenbæk. (2007) Cost-effectiveness of GRAZAX® for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respiratory Medicine 101:9, 1885-1894
CrossRef158
Linda Cox, James T. Li, Harold Nelson, Richard Lockey. (2007) Allergen immunotherapy: A practice parameter second update. Journal of Allergy and Clinical Immunology 120:3, S25-S85
CrossRef159
M. A. Rank, J. T. C. Li. (2007) Allergen Immunotherapy. Mayo Clinic Proceedings 82:9, 1119-1123
CrossRef160
Julia M. Martínez Gómez, Stefan Fischer, Noèmi Csaba, Thomas M. Kündig, Hans P. Merkle, Bruno Gander, Pål Johansen. (2007) A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles. Pharmaceutical Research 24:10, 1927-1935
CrossRef161
Jeffrey M. Lehman, Phillip L. Lieberman. (2007) Office-Based Management of Allergic Rhinitis in Adults. The American Journal of Medicine 120:8, 659-663
CrossRef162
S. R. Durham, B. Riis. (2007) Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 62:8, 954-957
CrossRef163
Pål Johansen, Julia M Martínez Gómez, Bruno Gander. (2007) Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. Expert Review of Vaccines 6:4, 471-474
CrossRef164
Linda Cox, John R. Cohn. (2007) Duration of allergen immunotherapy in respiratory allergy: when is enough, enough?. Annals of Allergy, Asthma & Immunology 98:5, 416-426
CrossRef165
Hans Keiding, Kasper P. Jørgensen. (2007) A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. Current Medical Research and Opinion 23:5, 1113-1120
CrossRef166
C. Bachert, U. Vestenbæk, J. Christensen, U. K. Griffiths, P. B. Poulsen. (2007) Cost-effectiveness of grass allergen tablet (GRAZAX
) for the prevention of seasonal grass pollen induced rhinoconjunctivitis ? a Northern European perspective. Clinical & Experimental Allergy 37:5, 772-779
CrossRef167
L KEMENY, A KORECK. (2007) Ultraviolet light phototherapy for allergic rhinitis. Journal of Photochemistry and Photobiology B: Biology 87:1, 58-65
CrossRef168
Giovanni B. Pajno. (2007) Sublingual immunotherapy: The optimism and the issues. Journal of Allergy and Clinical Immunology 119:4, 796-801
CrossRef169
Stephen R. Durham. (2007) Tradition and innovation: Finding the right balance. Journal of Allergy and Clinical Immunology 119:4, 792-795
CrossRef170
Harold S. Nelson. (2007) Allergen immunotherapy: Where is it now?. Journal of Allergy and Clinical Immunology 119:4, 769-777
CrossRef171
Giovanni Passalacqua, Stephen R. Durham. (2007) Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapy. Journal of Allergy and Clinical Immunology 119:4, 881-891
CrossRef172
M. Larché. (2007) Peptide immunotherapy for allergic diseases. Allergy 62:3, 325-331
CrossRef173
Franco Borghesan, Daniela Bernardi, Mario Plebani. (2007) In vivo and in vitro allergy diagnostics: it's time to reappraise the costs. Clinical Chemistry and Laboratory Medicine 45:3, 391-395
CrossRef174
E. William St. Clair, Larry A. Turka, Andrew Saxon, Jeffrey B. Matthews, Mohamed H. Sayegh, George S. Eisenbarth, Jeffrey Bluestone. (2007) New Reagents on the Horizon for Immune Tolerance. Annual Review of Medicine 58:1, 329-346
CrossRef175
Ernesto Enrique, Anna Cisteró-Bahíma. (2007) Specific immunotherapy for food allergy: basic principles and clinical aspects. Current Opinion in Internal Medicine 6:1, 1-4
CrossRef176
Reto Crameri, Claudio Rhyner. (2007) Impact of Native, Recombinant, and Cross-Reactive Allergens on Humoral and T-Cell–Mediated Immune Responses. Immunology and Allergy Clinics of North America 27:1, 65-78
CrossRef177
Moises A Calderon, Bernadette Alves, Mikila Jacobson, Brian Hurwitz, Aziz Sheikh, Stephen Durham, Moises A Calderon. 2007. Allergen injection immunotherapy for seasonal allergic rhinitis. .
CrossRef178
Sabina Rak, William H. Yang, Martin R. Pedersen, Stephen R. Durham. (2007) Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: A double-blind, randomised study. Quality of Life Research 16:2, 191-201
CrossRef179
Philippe Stock, Claudia Rolinck-Werninghaus, Ulrich Wahn, Eckard Hamelmann. (2007) The Role of Anti-IgE Therapy in Combination with Allergen Specific Immunotherapy for Seasonal Allergic Rhinitis. BioDrugs 21:6, 403-410
CrossRef180
TAKAO FUJISAWA. (2007) Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunollogy 21:1, 21-27
CrossRef181
Ariana D. Buchanan, Todd D. Green, Stacie M. Jones, Amy M. Scurlock, Lynn Christie, Karen A. Althage, Pamela H. Steele, Laurent Pons, Rick M. Helm, Laurie A. Lee, A. Wesley Burks. (2007) Egg oral immunotherapy in nonanaphylactic children with egg allergy. Journal of Allergy and Clinical Immunology 119:1, 199-205
CrossRef182
Anu K. Immonen, Antti H. Taivainen, Ale T. O. Närvänen, Tuure T. Kinnunen, Soili A. Saarelainen, Marja A. Rytkönen-Nissinen, Tuomas I. Virtanen. (2007) Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f
CrossRef183
Creticos, Peter S., Schroeder, John T., Hamilton, Robert G., Balcer-Whaley, Susan L., Khattignavong, Arouna P., Lindblad, Robert, Li, Henry, Coffman, Robert, Seyfert, Vicki, Eiden, Joseph J., Broide, David, the Immune Tolerance Network Group. (2006) Immunotherapy with a Ragweed–Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis. New England Journal of Medicine 355:14, 1445-1455
Full Text184
E. Alvarez-Cuesta, J. Bousquet, G. W. Canonica, S. R. Durham, H.-J. Malling, E. Valovirta. (2006) Standards for practical allergen-specific immunotherapy. Allergy 61:s82, 1-3
CrossRef185
Piyush Patel, Anne Marie F Salapatek. (2006) Pollinex ® Quattro: a novel and well–tolerated, ultra short–course allergy vaccine. Expert Review of Vaccines 5:5, 617-629
CrossRef186
A. Aslam, B. Kessler, M. Batycka, C. A. O'Callaghan, S. A. Misbah, D. A. Warrell, G. Ogg. (2006) Defining the T cell antigen proteome of wasp venom. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 36:10, 1274-1280
CrossRef187
(2006) Subcutaneous immunotherapy. Allergy 61:s82, 5-13
CrossRef188
Mark Larché, Cezmi A. Akdis, Rudolf Valenta. (2006) Immunological mechanisms of allergen-specific immunotherapy. Nature Reviews Immunology 6:10, 761-771
CrossRef189
Steven J. McEldowney, Robert K. Bush. (2006) Pollen immunotherapy: Selection, prevention, and future directions. Current Allergy and Asthma Reports 6:5, 420-426
CrossRef190
Christopher L. Kepley. (2006) New approaches to allergen immunotherapy. Current Allergy and Asthma Reports 6:5, 427-433
CrossRef191
Melanie Werner-Klein, Frank Kalkbrenner, Klaus J Erb. (2006) Sublingual immunotherapy of allergic diseases. Expert Opinion on Drug Delivery 3:5, 599-612
CrossRef192
Giovanni Passalacqua, Laura Guerra, Enrico Compalati, Federica Fumagalli, Arianna Cirillo, Giorgio Walter Canonica. (2006) New insights in sublingual immunotherapy. Current Allergy and Asthma Reports 6:5, 407-412
CrossRef193
Bhanu P. Singh, Banani Banerjee, Puspanita Naik, Jordan N. Fink, Viswanath P. Kurup. (2006) Immune response to n-terminal and c-terminal deletion mutants of Aspergillus fumigatus major allergen ASP F 3. Indian Journal of Clinical Biochemistry 21:2, 20-27
CrossRef194
Linda Cox. (2006) Allergen immunotherapy: immunomodulatory treatment for allergic diseases. Expert Review of Clinical Immunology 2:4, 533-546
CrossRef195
Giovanni B Pajno. (2006) Status of immunotherapy: is the time ripe for the secondary prevention of asthma and allergy?. Expert Review of Clinical Immunology 2:4, 485-487
CrossRef196
A. Didier. (2006) Future developments in sublingual immunotherapy. Allergy 61:s81, 29-31
CrossRef197
Nariman Aghaei Bandbon Balenga, Farnaz Zahedifard, Richard Weiss, Mohammad Nabi Sarbolouki, Joseph Thalhamer, Sima Rafati. (2006) Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy. Journal of Biotechnology 124:3, 602-614
CrossRef198
M. L. Kowalski. (2006) Systemic and specific treatment for a global disease: allergen immunotherapy revisited. Allergy 61:7, 791-795
CrossRef199
M. Jutel, M. Akdis, K. Blaser, C. A. Akdis. (2006) Mechanisms of allergen specific immunotherapy - T-cell tolerance and more. Allergy 61:7, 796-807
CrossRef200
B. Niggemann, L. Jacobsen, S. Dreborg, H. A. Ferdousi, S. Halken, A. Host, A. Koivikko, D. Koller, L. A. Norberg, R. Urbanek, E. Valovirta, U. Wahn, C. Moller, . (2006) Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 61:7, 855-859
CrossRef201
Lucie Heinzerling, Margitta Worm, Karl-Christian Bergmann, Torsten Zuberbier. (2006) Sublingual immunotherapy. Journal der Deutschen Dermatologischen Gesellschaft 4:5, 428-434
CrossRef202
Norbert H
CrossRef203
M. Tarzi, S. Klunker, C. Texier, A. Verhoef, S. O. Stapel, C. A. Akdis, B. Maillere, A. B. Kay, M. Larche. (2006) Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 36:4, 465-474
CrossRef204
Alison Taylor, Johan Verhagen, Kurt Blaser, Mubeccel Akdis, Cezmi A. Akdis. (2006) Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 117:4, 433-442
CrossRef205
Ohashi Yoshihiro, Nakai Yoshinori, Murata Kiyotaka. (2006) Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis. Annals of Allergy, Asthma & Immunology 96:4, 600-605
CrossRef206
A. M. Ejrnaes, M. Svenson, G. Lund, J. N. Larsen, H. Jacobi. (2006) Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy -induced serum immunoglobulin G: no evidence that FcgammaRIIB signalling is important. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 36:3, 273-282
CrossRef207
R. Dahl, A. Stender, S. Rak. (2006) Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.. Allergy 61:2, 185-190
CrossRef208
Graham Roberts, Catriona Hurley, Victor Turcanu, Gideon Lack. (2006) Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. Journal of Allergy and Clinical Immunology 117:2, 263-268
CrossRef209
David B.K. Golden. (2006) Insect sting allergy and venom immunotherapy. Annals of Allergy, Asthma & Immunology 96:2, S16-S21
CrossRef210
P. A. Eng, M. Borer-Reinhold, I. A. F. M. Heijnen, H. P. E. Gnehm. (2006) Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood.. Allergy 61:2, 198-201
CrossRef211
Verena Niederberger, Rudolf Valenta. (2006) Molecular approaches for new vaccines against allergy. Expert Review of Vaccines 5:1, 103-110
CrossRef212
Anthony J. Frew, Richard J. Powell, Christopher J. Corrigan, Stephen R. Durham. (2006) Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology 117:2, 319-325
CrossRef213
Mark Kendall, Thomas J. Mitchell, George Costigan, Mark Armitage, Jason C. Lenzo, Jennifer A. Thomas, Christophe von Garnier, Graeme R. Zosky, Debra J. Turner, Phil A. Stumbles, Peter D. Sly, Patrick G. Holt, Wayne R. Thomas. (2006) Downregulation of IgE antibody and allergic responses in the lung by epidermal biolistic microparticle delivery. Journal of Allergy and Clinical Immunology 117:2, 275-282
CrossRef214
Alan W Wheeler, Stefan R Woroniecki. (2006) Modern approaches to therapeutic vaccination as treatment for Type 1 respiratory hypersensitivity (allergy) treatment. Expert Review of Vaccines 5:1, 27-31
CrossRef215
Yeong-Ho Rha. (2006) Allergic rhinitis in children : diagnosis and treatment. Korean Journal of Pediatrics 49:6, 593
CrossRef216
Filip K. Swirski, Abigail D’Sa, Sussan Kianpour, Mark D. Inman, Martin R. Stämpfli. (2006) Prolonged Ovalbumin Exposure Attenuates Airway Hyperresponsiveness and T Cell Function in Mice. International Archives of Allergy and Immunology 141:2, 130-140
CrossRef217
Alexander N. Greiner. (2006) Allergic Rhinitis: Impact of the Disease and Considerations for Management. Medical Clinics of North America 90:1, 17-38
CrossRef218
Kyung Won Kim, Eun Ah Kim, Byoung Chul Kwon, Eun Soo Kim, Tae Won Song, Myung Hyun Sohn, Kyu-Earn Kim. (2006) Comparison of Allergic Indices in Monosensitized and Polysensitized Patients with Childhood Asthma. Journal of Korean Medical Science 21:6, 1012
CrossRef219
DAISUKE HATA. (2006) Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunollogy 20:1, 59-65
CrossRef220
Marek Jutel. (2006) Ultra-Short-Course Seasonal Allergy Vaccine (Pollinex?? Quattro). Drugs 66:7, 939-940
CrossRef221
Paul L McCormack, Antona J Wagstaff. (2006) Ultra-Short-Course Seasonal Allergy Vaccine (Pollinex?? Quattro). Drugs 66:7, 931-938
CrossRef222
P. Johansen, G. Senti, J. M. Martinez Gomez, T. Storni, B. R. Beust, B. Wuthrich, A. Bot, T. M. Kundig. (2005) Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 35:12, 1591-1598
CrossRef223
F Runa Ali, Mark Larché. (2005) Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Review of Vaccines 4:6, 881-889
CrossRef224
James N Francis, Mark Larché. (2005) Peptide-based vaccination: where do we stand?. Current Opinion in Allergy and Clinical Immunology 5:6, 537-543
CrossRef225
Pål Johansen, Gabriela Senti, Julia Maria Martínez Gómez, Brunello Wüthrich, Adrian Bot, Thomas M. Kündig. (2005) Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. European Journal of Immunology 35:12, 3591-3598
CrossRef226
Mark Larché. (2005) Peptide therapy for allergic diseases: Basic mechanisms and new clinical approaches. Pharmacology & Therapeutics 108:3, 353-361
CrossRef227
Plaut, Marshall, Valentine, Martin D., . (2005) Allergic Rhinitis. New England Journal of Medicine 353:18, 1934-1944
Full Text228
Riccardo Asero, Bernhard Weber, Gianni Mistrello, Stefano Amato, Enzo Madonini, Oliver Cromwell. (2005) Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences between short and giant ragweed. Journal of Allergy and Clinical Immunology 116:5, 1036-1041
CrossRef229
Ai-lin TAO, Shao-heng HE. (2005) Cloning, expression, and characterization of pollen allergens from Humulus scandens (Lour) Merr and Ambrosia artemisiifolia L1. Acta Pharmacologica Sinica 26:10, 1225-1232
CrossRef230
D. Infuhr, R. Crameri, R. Lamers, G. Achatz. (2005) Molecular and cellular targets of anti-IgE antibodies. Allergy 60:8, 977-985
CrossRef231
B. K. Ballmer-Weber, A. Wangorsch, B. Bohle, S. Kaul, T. Kundig, K. Fotisch, R. van Ree, S. Vieths. (2005) Component-resolved in vitro diagnosis in carrot allergy: Does the use of recombinant carrot allergens improve the reliability of the diagnostic procedure?. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 35:7, 970-978
CrossRef232
H. Riechelmann. (2005) Immuntherapie mit Allergenextrakten bei allergischer Rhinitis. HNO 53:6, 517-530
CrossRef233
F. Puggioni, S. R. Durham, J. N. Francis. (2005) Monophosphoryl lipid A (MPLR)* promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 60:5, 678-684
CrossRef234
Giovanni B. Pajno. (2005) Allergen immunotherapy in early childhood: between Scylla and Charybdis!. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 35:5, 551-553
CrossRef235
Mark Larché, David C Wraith. (2005) Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nature Medicine 11:4s, S69-S76
CrossRef236
Carlos E Baena-Cagnani, Giovanni Passalacqua, Rodrigo C Baena-Cagnani, Victor H Croce, Walter G Canonica. (2005) Sublingual immunotherapy in pediatric patients: beyond clinical efficacy. Current Opinion in Allergy and Clinical Immunology 5:2, 173-177
CrossRef237
Valeria Corti, Angela Cattaneo, Angela Bachi, Renato E. Rossi, Giorgio Monasterolo, Clara Paolucci, Samuele E. Burastero, Massimo Alessio. (2005) Identification of grass pollen allergens by two-dimensional gel electrophoresis and serological screening. PROTEOMICS 5:3, 729-736
CrossRef238
Cezmi A Akdis. (2005) Future of allergen-specific immunotherapy. Expert Opinion on Emerging Drugs 10:1, 1-4
CrossRef239
William E Berger. (2005) The Safety and Efficacy of Desloratadine for the Management of Allergic Disease. Drug Safety 28:12, 1101-1118
CrossRef240
K.D. Petersen, D. Gyrd-Hansen, R. Dahl. (2005) Health-Economic Analyses of subcutaneous Specific Immunotherapy for grass pollen and mite allergy. Allergologia et Immunopathologia 33:6, 296-302
CrossRef241
D. R. Wilson, M. Torres Lima, S. R. Durham. (2005) Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60:1, 4-12
CrossRef242
Wiqar A Shaikh. (2005) Long-term Efficacy of House Dust Mite Immunotherapy in Bronchial Asthma: A 15-year Follow-up Study. Allergology International 54:3, 443-449
CrossRef243
Norbert Reider. (2005) Sublingual Immunotherapy for Allergic Rhinoconjunctivitis – The Seeming and the Real. International Archives of Allergy and Immunology 137:3, 181-186
CrossRef244
Riccardo Asero. (2005) Lack of de novo Sensitization to Tropomyosin in a Group of Mite-Allergic Patients Treated by House Dust Mite-Specific Immunotherapy. International Archives of Allergy and Immunology 137:1, 62-65
CrossRef245
G. Senti, P. Johansen, J. Martinez Gomez, B. M. Prinz Varicka, T. M. Kündig. (2005) Efficacy and Safety of Allergen-Specific Immunotherapy in Rhinitis, Rhinoconjunctivitis, and Bee/Wasp Venom Allergies. International Reviews of Immunology 24:5-6, 519-531
CrossRef246
A KORECK, Z CSOMA, M BOROSGYEVI, F IGNACZ, L BODAI, A DOBOZY, L KEMENY. (2004) Inhibition of immediate type hypersensitivity reaction by combined irradiation with ultraviolet and visible light. Journal of Photochemistry and Photobiology B: Biology 77:1-3, 93-96
CrossRef247
H. Plewako, M. Arvidsson, I. Oancea, B. Hasseus, U. Dahlgren, S. Rak. (2004) The effect of specific immunotherapy on the expression of costimulatory molecules in late phase reaction of the skin in allergic patients. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 34:12, 1862-1867
CrossRef248
Cezmi A Akdis, Kurt Blaser, Mübeccel Akdis. (2004) Apoptosis in tissue inflammation and allergic disease. Current Opinion in Immunology 16:6, 717-723
CrossRef249
James N Francis, Stephen R Durham. (2004) Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Current Opinion in Allergy and Clinical Immunology 4:6, 543-548
CrossRef250
David Broide. (2004) Immunomodulation and reversal of airway remodeling in asthma. Current Opinion in Allergy and Clinical Immunology 4:6, 529-532
CrossRef251
Fernando Maria de Benedictis, Fabrizio Franceschini, Virgilio Carnielli, Giorgio Tonietti. (2004) Strategies for early prevention of asthma. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy Reviews 4:s2, 246-251
CrossRef252
C. Rolinck-Werninghaus, H. Wolf, C. Liebke, J. C. Baars, J. Lange, M. V. Kopp, J. Hammermann, W. Leupold, P. Bartels, A. Gruebl, C. P. Bauer, J. Schnitker, U. Wahn, B. Niggemann. (2004) A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 59:12, 1285-1293
CrossRef253
R. Asero. (2004) Effects of birch pollen SIT on apple allergy: a matter of dosage?. Allergy 59:12, 1269-1271
CrossRef254
Stephanie C Eisenbarth, Suzanne Cassel, Kim Bottomly. (2004) Understanding asthma pathogenesis: linking innate and adaptive immunity. Current Opinion in Pediatrics 16:6, 659-666
CrossRef255
Douglas S. Robinson, Mark Larché, Stephen R. Durham. (2004) Tregs and allergic disease. Journal of Clinical Investigation 114:10, 1389-1397
CrossRef256
T. R. F. Smith, C. Alexander, A. B. Kay, M. Larche, D. S. Robinson. (2004) Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double-blind placebo-controlled study. Allergy 59:10, 1097-1101
CrossRef257
L. K. Wilcock, J. N. Francis, S. R. Durham. (2004) Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 34:9, 1373-1378
CrossRef258
C. A. Akdis, K. Blaser, M. Akdis. (2004) Genes of tolerance. Allergy 59:9, 897-913
CrossRef259
Melinda M. Rathkopf, James M. Quinn, David L. Proffer, Diane C. Napoli. (2004) Patient knowledge of immunotherapy before and after an educational intervention: a comparison of 2 methods. Annals of Allergy, Asthma & Immunology 93:2, 147-153
CrossRef260
Soichi Tanabe, Rumiko Shibata, Toshihide Nishimura. (2004) Hypoallergenic and T cell reactive analogue peptides of bovine serum albumin, the major beef allergen. Molecular Immunology 41:9, 885-890
CrossRef261
C. Bez, R. Schubert, M. Kopp, Y. Ersfeld, M. Rosewich, J. Kuehr, W. Kamin, A. V. Berg, U. Wahu, S. Zielen. (2004) Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 34:7, 1079-1085
CrossRef262
, J. Bousquet, P. van Cauwenberge, N. Khaltaev. (2004) ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic Rhinitis and its Impact on Asthma. Allergy 59:4, 373-387
CrossRef263
Chitra Dinakar, Jay M Portnoy. (2004) Allergen immunotherapy in the prevention of asthma. Current Opinion in Allergy and Clinical Immunology 4:2, 131-136
CrossRef264
K. Blaser, C. A. Akdis. (2004) Interleukin-10, T regulatory cells and specific allergy treatment. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 34:3, 328-331
CrossRef265
I. Ibarrola, M. L. Sanz, P. M. Gamboa, A. Mir, D. Benahmed, A. Ferrer, M. C. Arilla, A. Martinez, J. A. Asturias. (2004) Biological characterization of glutaraldehyde-modified Parietaria judaica pollen extracts. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 34:2, 303-309
CrossRef266
Virat Kirtsreesakul, Robert M Naclerio. (2004) Role of allergy in rhinosinusitis. Current Opinion in Allergy and Clinical Immunology 4:1, 17-23
CrossRef267
Hans Michael Haitchi, Stephen T Holgate. (2004) New strategies in the treatment and prevention of allergic diseases. Expert Opinion on Investigational Drugs 13:2, 107-124
CrossRef268
A. Hartl, R. Hochreiter, T. Stepanoska, F. Ferreira, J. Thalhamer. (2004) Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v 1a. Allergy 59:1, 65-73
CrossRef269
M. S. Khinchi, L. K. Poulsen, F. Carat, C. Andre, A. B. Hansen, H.-J. Malling. (2004) Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59:1, 45-53
CrossRef270
William E Berger. (2004) Allergic Rhinitis in Children. Pediatric Drugs 6:4, 233-250
CrossRef271
Maria G Belvisi, David J Hele, Mark A Birrell. (2004) New Advances and Potential Therapies for the Treatment of Asthma. BioDrugs 18:4, 211-223
CrossRef272
Thomas Christian Roos, Stefan Geuer, Sabine Roos, Harald Brost. (2004) Recent Advances in Treatment Strategies for Atopic Dermatitis. Drugs 64:23, 2639-2666
CrossRef273
Elizabeth C. TePas, Elisabeth G. Hoyte, Jennifer J. McIntire, Dale T. Umetsu. (2004) Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals. Annals of Allergy, Asthma & Immunology 92:1, 25-31
CrossRef274
Riccardo Asero. (2004) Efficacy of Injection Immunotherapy with Ragweed and Birch Pollen in Elderly Patients. International Archives of Allergy and Immunology 135:4, 332-335
CrossRef275
Larry Borish. (2003) Allergic rhinitis. Journal of Allergy and Clinical Immunology 112:6, 1021-1031
CrossRef276
Graham S. Ogg. (2003) T-cell immunotherapy of allergic disease: the role of CD8+ T cells. Current Opinion in Allergy and Clinical Immunology 3:6, 475-479
CrossRef277
Kirsi Laaksonen, Miia Junikka, Riitta Lahesmaa, Erkki O Terho, Johannes Savolainen. (2003) In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. Journal of Allergy and Clinical Immunology 112:6, 1171-1177
CrossRef278
G.-J. Braunstahl, W. Fokkens. (2003) Nasal involvement in allergic asthma. Allergy 58:12, 1235-1243
CrossRef279
Eckard Hamelmann, Claudia Rolinck-Werninghaus, Ulrich Wahn. (2003) Is there a role for anti-IgE in combination with specific allergen immunotherapy?. Current Opinion in Allergy and Clinical Immunology 3:6, 501-510
CrossRef280
K.-Y. Hsieh, C.-I. Hsu, J.-Y. Lin, C.-C. Tsai, R.-H. Lin. (2003) Oral administration of an edible-mushroom-derived protein inhibits the development of food-allergic reactions in mice. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 33:11, 1595-1602
CrossRef281
Lily H. P. Nguyen, Samer Fakhri, Saul Frenkiel, Qutayba A. Hamid. (2003) Molecular immunology and immunotherapy for chronic sinusitis. Current Allergy and Asthma Reports 3:6, 505-512
CrossRef282
Douglas S. Robinson. (2003) New therapies for asthma: Where next?. Pediatric Pulmonology 36:5, 369-375
CrossRef283
Stephen T. Holgate, David Broide. (2003) New targets for allergic rhinitis — a disease of civilization. Nature Reviews Drug Discovery 2:11, 903-915
CrossRef284
Petra A Wachholz, Nanna Kristensen Soni, Stephen J Till, Stephen R Durham. (2003) Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. Journal of Allergy and Clinical Immunology 112:5, 915-922
CrossRef285
Michael J Abramson, Robert M Puy, John M Weiner, Michael J Abramson. 2003. Allergen immunotherapy for asthma. .
CrossRef286
Kelly D. Stone. (2003) Atopic diseases of childhood. Current Opinion in Pediatrics 15:5, 495-511
CrossRef287
Arthur Helbling, Andrea Reimers. (2003) Immunotherapy in fungal allergy. Current Allergy and Asthma Reports 3:5, 447-453
CrossRef288
P. A. Wachholz, S. R. Durham. (2003) Induction of 'blocking' IgG antibodies during immunotherapy. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 33:9, 1171-1174
CrossRef289
S. Walker, A. Sheikh. (2003) Managing anaphylaxis: effective emergency and long-term care are necessary. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 33:8, 1015-1018
CrossRef290
Terreehorst, Ingrid, Hak, Eelko, Oosting, Albert J., Tempels-Pavlica, Zana, de Monchy, Jan G.R., Bruijnzeel-Koomen, Carla A.F.M., Aalberse, Rob C., Gerth van Wijk, Roy, . (2003) Evaluation of Impermeable Covers for Bedding in Patients with Allergic Rhinitis. New England Journal of Medicine 349:3, 237-246
Full Text291
Michael Tarzi, Mark Larché. (2003) Peptide immunotherapy for allergic disease. Expert Opinion on Biological Therapy 3:4, 617-626
CrossRef292
R. Polosa, F. Li Gotti, G. Mangano, C. Mastruzzo, M. P. Pistorio, N. Crimi. (2003) Monitoring of seasonal variability in bronchial hyper-responsiveness and sputum cell counts in non-asthmatic subjects with rhinitis and effect of specific immunotherapy. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 33:7, 873-881
CrossRef293
K. Jahnz-Rozyk, T. Targowski, E. Glodzinska-Wyszogrodzka, T. Plusa. (2003) Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis. Allergy 58:7, 595-601
CrossRef294
A. Bufe. (2003) Neue Therapeutische Ansätze der Immunmodulation bei allergischen Erkrankungen/Novel Therapeutic Concepts for Immunomodulation of Allergic Diseases. LaboratoriumsMedizin 27:5-6, 201-203
CrossRef295
Smruti A. Parikh, Seong H. Cho, Chad K. Oh. (2003) Preformed enzymes in mast cell granules and their potential role in allergic rhinitis. Current Allergy and Asthma Reports 3:3, 266-272
CrossRef296
R. Asero. (2003) How long does the effect of birch pollen injection SIT on apple allergy last?. Allergy 58:5, 435-438
CrossRef297
Hans-Jørgen Malling. (2003) Immunotherapy for rhinitis. Current Allergy and Asthma Reports 3:3, 204-209
CrossRef298
K. Sade, S. Kivity, A. Levy, E. Fireman. (2003) The effect of specific immunotherapy on T-cell receptor repertoire in patients with allergy to house-dust mite. Allergy 58:5, 430-434
CrossRef299
Duncan Wilson, Marcia Torres-Lima, Stephen Durham, Duncan Wilson. 2003. Sublingual immunotherapy for allergic rhinitis. .
CrossRef300
Giovanni Passalacqua, Carlos E. Baena-Cagnani, Michele Berardi, Giorgio Walter Canonica. (2003) Oral and sublingual immunotherapy in paediatric patients. Current Opinion in Allergy and Clinical Immunology 3:2, 139-145
CrossRef301
Ling-Hua Wang, Yao-Hsu Yang, Ming-Jer Tsai, Bor-Luen Chiang. (2003) The Changes of Mite-Specific Immunoglobulin A and Transforming Growth Factor-β1 During Immunotherapy of Children with Dust Mite Allergy. Pediatric Asthma, Allergy & Immunology 16:1, 15-22
CrossRef302
Robert Movérare. (2003) Immunological mechanisms of specific immunotherapy with pollen vaccines: implications for diagnostics and the development of improved vaccination strategies. Expert Review of Vaccines 2:1, 85-97
CrossRef303
John J. Murray, Csaba Rusznak. (2003) Asthma and rhinosinusitis. Current Opinion in Otolaryngology & Head and Neck Surgery 11:1, 49-53
CrossRef304
V. Di Rienzo, F. Marcucci, P. Puccinelli, S. Parmiani, F. Frati, L. Sensi, G. W. Canonica, G. Passalacqua. (2003) Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 33:2, 206-210
CrossRef305
Ira Finegold. (2003) A significant evolutionary step in the specialty of allergy and immunology. Annals of Allergy, Asthma & Immunology 90:1, 13-14
CrossRef306
James T. Li, Richard F. Lockey, I. Leonard Bernstein, Jay M. Portnoy, Richard A. Nicklas. (2003) Allergen immunotherapy: a practice parameter. Annals of Allergy, Asthma & Immunology 90:1, 1-40
CrossRef307
Gert-Jan Braunstahl, Peter W. Hellings. (2003) Allergic rhinitis and asthma: the link further unraveled. Current Opinion in Pulmonary Medicine 9:1, 46-51
CrossRef308
Ira Finegold. (2002) Is immunotherapy effective in allergic disease?. Current Opinion in Allergy and Clinical Immunology 2:6, 537-540
CrossRef309
Hans Gronlund, Susanne Vrtala, Ursula Wiedermann, Gerhard Dekan, Dietrich Kraft, Rudolf Valenta, Marianne Van Hage-Hamsten. (2002) Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology 107:4, 523-529
CrossRef310
Jennifer M Rolland, Robyn E O'Hehir. (2002) Allergen immunotherapy: Current and new therapeutic strategies. Allergology International 51:4, 221-231
CrossRef311
Ulrich Wahn. (2002) Immunotherapy in children. Current Opinion in Allergy and Clinical Immunology 2:6, 557-560
CrossRef312
Jonathan Corren, Thomas Casale. (2002) Immunomodulation of asthma: Where do we stand?. Current Allergy and Asthma Reports 2:6, 433-435
CrossRef313
E. Hamelmann, C. Rolinck-Werninghaus, U. Wahn. (2002) From IgE to Anti-IgE: Where do we stand?. Allergy 57:11, 983-994
CrossRef314
G. Passalacqua, G.W. Canonica. (2002) Treating the allergic patient: think globally, treat globally. Allergy 57:10, 876-883
CrossRef315
Iftikhar Hussain, Vipul V. Jain, Kunihiko Kitagaki, Thomas R. Businga, Patrick O???Shaughnessy, Joel N. Kline. (2002) Modulation of Murine Allergic Rhinosinusitis by CpG Oligodeoxynucleotides. The Laryngoscope 112:10, 1819-1826
CrossRef316
Leonard Bielory, Anu Mongia. (2002) Current opinion of immunotherapy for ocular allergy. Current Opinion in Allergy and Clinical Immunology 2:5, 447-452
CrossRef317
Nina C Ramirez, Dennis K Ledford. (2002) Immunotherapy for allergic asthma. Medical Clinics of North America 86:5, 1091-1112
CrossRef318
John M. Kelso. (2002) Recurrence of allergic rhinitis, previously alleviated with allergen immunotherapy, after autologous bone marrow transplant. Annals of Allergy, Asthma & Immunology 89:3, 316-318
CrossRef319
J. Bousquet, P. van Cauwenberge, N. Khaltaev. (2002) Executive Summary of the Workshop Report 7-10 December 1999, Geneva, Switzerland. Allergy 57:9, 841-855
CrossRef320
Patricia Leonard, Sanjiv Sur. (2002) Asthma: future directions. Medical Clinics of North America 86:5, 1131-1156
CrossRef321
R. Naclerio, L. Rosenwasser, K. Ohkubo. (2002) Allergic rhinitis: current and future treatments. Clinical & Experimental Allergy Reviews 2:4, 137-147
CrossRef322
WLG Oldfield, M Larché, AB Kay. (2002) Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. The Lancet 360:9326, 47-53
CrossRef323
Robert G Townley, Russell J Hopp, Devendra K Agrawal, Thomas B Casale, Michael T Hopfenspirger. (2002) Immunomodulation in the treatment and/or prevention of bronchial asthma. Allergology International 51:2, 63-73
CrossRef324
Mamidipudi T. Krishna, Sundeep S. Salvi. (2002) Could administration of bacille Calmette-Guerin vaccination at birth protect from the development of asthma and allergic diseases in the western world? Has this question been adequately investigated?. Pediatric Allergy and Immunology 13:3, 172-176
CrossRef325
R. Moverare, L. Elfman, E. Vesterinen, T. Metso, T. Haahtela. (2002) Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP Systemtm. Allergy 57:5, 423-430
CrossRef326
Carsten B. Schmidt-Weber, Steffen Kunzmann, Kurt Blaser. (2002) TGF-β-mediated control of allergen-specific t-cell responses. Current Allergy and Asthma Reports 2:3, 259-262
CrossRef327
Laurie A. Whittaker, Lauren Cohn. (2002) Recent Concepts in the Pathogenesis and Treatment of Asthma. Clinical Pulmonary Medicine 9:3, 135-144
CrossRef328
M. van Hage-Hamsten, R. Valenta. (2002) Specific immunotherapy - the induction of new IgE-specificities?. Allergy 57:5, 375-378
CrossRef329
A. Host, S. Halken. (2002) Can we apply clinical studies to real life?Evidence-based recommendations from studies on development of allergic diseases and allergy prevention. Allergy 57:5, 389-397
CrossRef330
J. Bousquet. (2002) The new ARIA guidelines: putting science into practice. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy Reviews 2:1, 38-43
CrossRef331
M. Torres Lima, D. Wilson, L. Pitkin, A. Roberts, K. Nouri-Aria, M. Jacobson, S. Walker, S. Durham. (2002) Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 32:4, 507-514
CrossRef332
G. Passalacqua, G. W. Canonica. (2002) Long-lasting clinical efficacy of allergen specific immunotherapy. Allergy 57:4, 275-276
CrossRef333
P. A. Eng, M. Reinhold, HP. E. Gnehm. (2002) Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 57:4, 306-312
CrossRef334
F. Runa Ali, A. Barry Kay, Mark Larché. (2002) The potential of peptide immunotherapy in allergy and asthma. Current Allergy and Asthma Reports 2:2, 151-158
CrossRef335
R. Michael Sly. (2002) Epidemiology of allergic rhinitis. Clinical Reviews in Allergy & Immunology 22:1, 67-103
CrossRef336
. (2002) Allergische rhinitis: immunotherapie versus farmacotherapie. Medisch-Farmaceutische Mededelingen 40:1, 16-17
CrossRef337
Petra A. Wachholz, Kayhan T. Nouri-Aria, Duncan R. Wilson, Samantha M. Walker, Adrienne Verhoef, Stephen J. Till, Stephen R. Durham. (2002) Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1 : Th2 cytokine ratios. Immunology 105:1, 56-62
CrossRef338
S. M. Shuaib Nasser, Sun Ying, Qiu Meng, A. Barry Kay, Pamela W. Ewan. (2001) Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. European Journal of Immunology 31:12, 3704-3713
CrossRef339
D. R. Wilson, A.-MA. Irani, S. M. Walker, M. R. Jacobson, I. S. Mackay, L. B. Schwartz, S. R. Durham. (2001) Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 31:11, 1705-1713
CrossRef340
Gisela Wohlleben, Klaus Joseph Erb. (2001) Atopic disorders: a vaccine around the corner?. Trends in Immunology 22:11, 618-626
CrossRef341
Stuart E. Turvey. (2001) Atopic diseases of childhood. Current Opinion in Pediatrics 13:5, 487-495
CrossRef342
Cezmi A. Akdis, Kurt Blaser. (2001) Role of IL-10 in allergen-specific immunotherapy and normal response to allergens. Microbes and Infection 3:11, 891-898
CrossRef343
Henning Løwenstein, Jørgen Nedergaard Larsen. (2001) Recombinant allergens/ allergen standardization. Current Allergy and Asthma Reports 1:5, 474-479
CrossRef344
F. Purello-D'Ambrosio, S. Gangemi, R. A. Merendino, S. Isola, P. Puccinelli, S. Parmiani, L. Ricciardi. (2001) Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 31:8, 1295-1302
CrossRef345
M. C. Arilla, I. Ibarrola, E. Eraso, M. Aguirre, A. Martinez, J. A. Asturias. (2001) Quantification in mass units of group 1 grass allergens by a monoclonal antibody-based sandwich ELISA. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 31:8, 1271-1278
CrossRef346
Lars Jacobsen. (2001) Preventive aspects of immunotherapy: prevention for children at risk of developing asthma. Annals of Allergy, Asthma & Immunology 87:1, 43-46
CrossRef347
F. Leynadier, L. Banoun, B. Dollois, P. Terrier, M. Epstein, M.-T. Guinnepain, D. Firon, C. Traube, R. Fadel, C. Andre. (2001) Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 31:7, 988-996
CrossRef348
S. Fearby, A. J. Frew. (2001) Hunting the magic bullet in immunotherapy: new forms of old treatment or something completely different?. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 31:7, 969-974
CrossRef349
Jean Bousquet, Pascal Demoly, François-B. Michel. (2001) Specific immunotherapy in rhinitis and asthma. Annals of Allergy, Asthma & Immunology 87:1, 38-42
CrossRef350
Jeanne A. Wohlfarth, Laura A. Peterson, W. T. Willoughby. (2001) Commercial laboratory preparation of immunotherapy vials. Current Opinion in Otolaryngology & Head and Neck Surgery 9:3, 186-192
CrossRef351
K. J. Drachenberg, A. W. Wheeler, P. Stuebner, F. Horak. (2001) A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56:6, 498-505
CrossRef352
William W. Mason. (2001) Status of standardized allergen extracts. Current Opinion in Otolaryngology & Head and Neck Surgery 9:3, 181-185
CrossRef353
Cezmi A. Akdis, Kurt Blaser. (2001) Mechanisms of interleukin-10-mediated immune suppression. Immunology 103:2, 131-136
CrossRef354
Ruby Pawankar, Wytske Fokkens. (2001) Evidence-based treatment of allergic rhinitis. Current Allergy and Asthma Reports 1:3, 218-226
CrossRef355
Mackay, Ian R., Rosen, Fred S., , Kamradt, Thomas, Mitchison, N. Avrion, . (2001) Tolerance and Autoimmunity. New England Journal of Medicine 344:9, 655-664
Full Text356
Ronald L. Morton, Shahid Sheikh, Mark L. Corbett, Nemr S. Eid. (2001) Evaluation of the wheezy infant. Annals of Allergy, Asthma & Immunology 86:3, 251-256
CrossRef357
Hans-J??rgen Malling. (2001) Allergen-specific immunotherapy in allergic rhinitis. Current Opinion in Allergy and Clinical Immunology 1:1, 43-46
CrossRef358
Christoph Walker, Claudia Zuany-Amorim. (2001) New trends in immunotherapy to prevent atopic diseases. Trends in Pharmacological Sciences 22:2, 84-90
CrossRef359
Mackay, Ian R., Rosen, Fred S., , Kay, A.B., . (2001) Allergy and Allergic Diseases. New England Journal of Medicine 344:2, 109-113
Full Text360
Giovanni Passalacqua, Giorgio Walter Canonica. (2001) Allergen-Specific Sublingual Immunotherapy for Respiratory Allergy. BioDrugs 15:8, 509-519
CrossRef361
Fulvio Mastrandrea. (2001) Immunotherapy in atopic dermatitis. Expert Opinion on Investigational Drugs 10:1, 49-63
CrossRef362
Anju Tripathi, Roy Patterson. (2001) Impact of Allergic Rhinitis Treatment on Quality of Life. PharmacoEconomics 19:9, 891-899
CrossRef363
Elizabeth C. TePas, Dale T. Umetsu. (2000) Immunotherapy of asthma and allergic diseases. Current Opinion in Pediatrics 12:6, 574-578
CrossRef364
Lauren Cohn, Anuradha Ray. (2000) T-helper type 2 cell-directed therapy for asthma. Pharmacology & Therapeutics 88:2, 187-196
CrossRef365
Peter J. Barnes. (2000) New directions in allergic diseases: Mechanism-based anti-inflammatory therapies. Journal of Allergy and Clinical Immunology 106:1, 5-16
CrossRef366
Harold S. Nelson. (2000) The use of standardized extracts in allergen immunotherapy. Journal of Allergy and Clinical Immunology 106:1, 41-45
CrossRef367
C. A. Akdis, K. Blaser. (2000) Mechanisms of allergen-specific immunotherapy. Allergy 55:6, 522-530
CrossRef368
Larche. (2000) Changes in interferon-gamma production following specific allergen immunotherapy: biology vs methodology. Clinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy 30:3, 297-300
CrossRef369
Jennifer M Rolland, Jo Douglass, Robyn E O’Hehir. (2000) Allergen immunotherapy: current and new therapeutic strategies. Expert Opinion on Investigational Drugs 9:3, 515-527
CrossRef370
Tse Wen Chang. (2000) The pharmacological basis of anti-IgE therapy. Nature Biotechnology 18:2, 157-162
CrossRef371
B Alves, A Sheikh, B Hurwitz, SR Durham, Bernadette Alves. 2000. Allergen injection immunotherapy for seasonal allergic rhinitis. .
CrossRef372
(2000) Clinical Efficacy of Grass-Pollen Immunotherapy. New England Journal of Medicine 342:1, 58-59
Full Text373
E. Alvarez-Cuesta, E. Gonzélez-Mancebo. (2000) Immunotherapy in bronchial asthma. Current Opinion in Pulmonary Medicine 6:1, 50-54
CrossRef374
A.B. Tonnel, F. Radenne, S. Desurmont. (2000) Prévention de l'asthme. Revue Française d'Allergologie et d'Immunologie Clinique 40:1, 135-138
CrossRef375
Adkinson, N. Franklin Jr., . (1999) Immunotherapy for Allergic Rhinitis. New England Journal of Medicine 341:7, 522-524
Full Text
- Letters
